

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 350 839 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
08.10.2003 Bulletin 2003/41

(51) Int Cl.7: C12N 1/36, A61K 39/04,
G01N 33/569, C12N 15/11,
C07K 14/35

(21) Application number: 02290864.4

(22) Date of filing: 05.04.2002

(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

• Majlessi, Laleh
78180 Montigny Le Bretonneux (FR)
• Leclerc, Claude
75015 Paris (FR)

(71) Applicant: INSTITUT PASTEUR
75015 Paris (FR)

(74) Representative: Warcoin, Jacques et al
Cabinet Régimbeau
20, rue de Chazelles
75847 Paris cedex 17 (FR)

(72) Inventors:

- Cole, Stewart
92140 Clamart (FR)
- Pym, Alexander S.
75015 Paris (FR)
- Brosch, Roland
75013 Paris (FR)
- Brodin, Priscille
75014 Paris (FR)

Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Identification of virulence associated regions RD1 and RD5 enabling the development of improved vaccines of *M. bovis* BCG and *M. microti***

(57) The present invention relates to a strain of *M. bovis* BCG or *M. microti*, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the *M. bovis* BCG::RD1 or *M. microti*::RD1

strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer.

EP 1 350 839 A1

Description

[0001] Virulence associated regions are searched for a long time in *Mycobacterium*. The present invention concerns the identification of 2 genomic regions which are shown to be associated with a virulent phenotype in *Mycobacteria* and particularly in *M. tuberculosis* and in *M. leprae*. It concerns also the fragments of said regions.

[0002] The two regions are known as RD1 and RD5 as disclosed in Molecular Microbiology (1999), vol. 32, pages 643 to 655 (Gordon S.V. et al.). Both of these regions or at least one of them are absent from the vaccine strains of *M. bovis* BCG and in *M. microti* strains found involved and used as live vaccines in the 1960's.

[0003] Other applications which are encompassed by the present invention are related to the use of all or part of the said regions to detect virulent strains of *Mycobacteria* and particularly *M. tuberculosis* in humans and animals. The RD1 and RD5 are considered as virulence markers under the present invention.

[0004] The recombinant *Mycobacteria* and particularly *M. bovis* BCG after modification of their genome by introduction of all part of RD1 region and/or RD5 region in said genome can be used for the immune system of patients affected with a cancer as for example a bladder cancer.

[0005] The present invention relates to a strain of *M. bovis* BCG or *M. microti*, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity to the tubercle bacilli, especially the genes coding ESAT-6 and CFP-10 antigens. These strains will be referred as the *M. bovis* BCG::RD1 or *M. microti*::RD1 strains and are useful as a new improved vaccine for prevention of tuberculosis infections and for treating superficial bladder cancer.

[0006] *Mycobacterium bovis* BCG (bacille Calmette-Guérin) has been used since 1921 to prevent tuberculosis although it is of limited efficacy against adult pulmonary disease in highly endemic areas. *Mycobacterium microti*, another member of the *Mycobacterium tuberculosis* complex, was originally described as the infective agent of a tuberculosis-like disease in voles (*Microtus agrestis*) in the 1930's (Wells, A. Q. 1937. Tuberculosis in wild voles. Lancet 1221 and Wells, A. Q. 1946. The murine type of tubercle bacillus. Medical Research council special report series 259:1-42.). Until recently, *M. microti* strains were thought to be pathogenic only for voles, but not for humans and some were even used as a live-vaccine. In fact, the vole bacillus proved to be safe and effective in preventing clinical tuberculosis in a trial involving roughly 10,000 adolescents in the UK in the 1950's (Hart, P. D. a., and I. Sutherland. 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. British Medical Journal 2: 293-295). At about the same time, another strain, OV166, was successfully administered to half a million newborns in Prague, former Czechoslovakia, without any serious complications (Sula, L., and I. Radkovsky. 1976. Protective effects of *M. microti* vaccine against tuberculosis. J. Hyg. Epid. Microbiol. Immunol. 20:1-6). *M. microti* vaccination has since been discontinued because it was no more effective than the frequently employed BCG vaccine. As a result, improved vaccines are needed for preventing and treating tuberculosis.

[0007] The problem for attempting to ameliorate this live vaccine is that the molecular mechanism of both the attenuation and the immunogenicity of BCG, is still poorly understood. Comparative genomic studies of all six members of the *M. tuberculosis* complex have identified more than 140 genes, whose presence is facultative, that may confer differences in phenotype, host range and virulence. Relative to the genome of the paradigm strain, *M. tuberculosis* H37Rv (S. T. Cole, et al., *Nature* 393, 537 (1998)), many of these genes occur in chromosomal regions that have been deleted from certain species (RD1-16, RvD1-5), M. A. Behr, et al., *Science* 284, 1520 (1999); R. Brosch, et al., *Infection Immun.* 66, 2221 (1998); S. V. Gordon, et al., *Molec Microbiol* 32, 643 (1999); H. Salomon, et al, *Genome Res* 10, 2044 (2000), G. G. Mahairas et al, *J. Bacteriol.* 178, 1274 (1996) and R. Brosch, et al., *Proc Natl Acad Sci USA* 99, 3684 (2002).

[0008] In connection with the invention and based on their distribution among tubercle bacilli and potential to encode virulence functions, RD1, RD3-5, RD7 and RD9 (Fig. 1A, B) were accorded highest priority for functional genomic analysis using "knock-ins" of *M. bovis* BCG to assess their potential contribution to the attenuation process. Clones spanning these RD regions were selected from an ordered *M. tuberculosis* H37Rv library of integrating shuttle cosmids (S. T. Cole, et al., *Nature* 393, 537 (1998) and W. R. Bange, et al, *Tuber. Lung Dis.* 79, 171 (1999)), and individually electroporated into BCG Pasteur, where they inserted stably into the *attB* site (M. H. Lee, et al, *Proc. Natl. Acad. Sci. USA* 88, 3111 (1991)).

[0009] We have uncovered that only reintroduction of RD1 led to profound phenotypic alteration. Strikingly, the BCG::RD1 "knock-in" grew more vigorously than BCG controls in immuno-deficient mice, inducing extensive splenomegaly and granuloma formation.

[0010] RD1 is restricted to the avirulent strains *M. bovis* BCG and *M. microti*. Although the endpoints are not identical, the deletions have removed from both vaccine strains a cluster of six genes (Rv3871-Rv3876) that are part of the ESAT-6 locus (Fig. 1A (S. T. Cole, et al., *Nature* 393, 537 (1998) and F. Tekaia, et al., *Tuberle Lung Disease* 79, 329 (1999)).

[0011] Among the missing products are members of the mycobacterial PE (Rv3872), PPE (Rv3873), and ESAT-6 (Rv3874, Rv3875) protein families. Despite lacking obvious secretion signals, ESAT-6 (Rv3875) and the related protein

CFP-10 (Rv3874), are abundant components of short-term culture filtrate, acting as immunodominant T-cell antigens that induce potent Th1 responses (F. Tekaia, et al., *Tubercle Lung Disease* 79, 329 (1999); A. L. Sorensen, et al., *Infect. Immun.* 63, 1710 (1995) and R. Colangelli, et al., *Infect. Immun.* 68, 990 (2000)).

[0012] In summary, we have discovered that the restoration of RD1 to *M. bovis* BCG leads to increased persistence in immunocompetent mice. The *M. bovis* BCG::RD1 strain induces RD1-specific immune responses of the Th1-type, has enhanced immunogenicity and confers better protection than *M. bovis* BCG alone in the mouse model of tuberculosis. The *M. bovis* BCG::RD1 vaccine is significantly more virulent than *M. bovis* BCG in immunodeficient mice but considerably less virulent than *M. tuberculosis*.

[0013] In addition, we show that *M. microti* lacks a different but overlapping part of the RD1 region (RD1^{mic}) to *M. bovis* BCG and our results indicate that reintroduction of RD1 confers increased virulence of BCG ::RD1 in immunodeficient mice. The rare strains of *M. microti* that are associated with human disease contain a region referred to as RD5^{mic} whereas those from voles do not.

[0014] *M. bovis* BCG vaccine could be improved by reintroducing other genes encoding ESAT-6 family members that have been lost, notably, those found in the RD8 and RD5 loci of *M. tuberculosis*. These regions also code for additional T-cell antigens.

[0015] *M. bovis* BCG::RD1 could be improved by reintroducing the RD8 and RD5 loci of *M. tuberculosis*.

[0016] *M. bovis* BCG vaccine could be improved by overexpressing the genes contained in the RD1, RD5 and RD8 regions.

[0017] Accordingly, these new strains, showing greater persistence and enhanced immunogenicity, represent an improved vaccine for preventing tuberculosis and treating bladder cancer.

[0018] In addition, the greater persistence of these recombinant stains is an advantage for the presentation of other antigens, for instance from HIV in humans and in order to induce protection immune responses. Those improved strains may also be of use in veterinary medicine, for instance in preventing bovine tuberculosis.

25 Description

[0019] Therefore, the present invention is aimed at a strain of *M. bovis* BCG or *M. microti*, wherein said strain has integrated all or part of the RD1 region responsible for enhanced immunogenicity to the tubercle bacilli. These strains will be referred as the *M. bovis* BCG::RD1 or *M. microti*::RD1 strains.

[0020] In connection with the invention, "part or all of the RD1 region" means that the strain has integrated a portion of DNA originating from *Mycobacterium tuberculosis*, which comprises at least one gene selected from Rv3871, Rv3872 (mycobacterial PE), Rv3873 (PPE), Rv3874 (CFP-10), Rv3875 (ESAT-6), and Rv3876. The expression gene is referred herein as the coding sequence in frame with its natural promoter as well as the coding sequence which has been isolated and framed with an exogenous promoter, for example a promoter capable of directing high level of expression of said coding sequence.

[0021] In a specific aspect, the invention relates to a strain of *M. bovis* BCG or *M. microti* wherein said strain has integrated at least one gene selected from Rv3871, Rv3872 (SEQ ID No 2, mycobacterial PE), Rv3873 (SEQ ID No 3, PPE), Rv3874 (SEQ ID No 4, CFP-10), Rv3875 (SEQ ID No 5, ESAT-6), and Rv3876, preferably CFP-10, ESAT-6 or both (SEQ ID No 6).

[0022] These genes can be mutated (deletion, insertion or base modification) so as to maintain the improved immunogenicity while decreasing the virulence of the strains. Using routine procedure, the man skilled in the art can select the *M. bovis* BCG::RD1 or *M. microti*::RD1 strains, in which a mutated gene has been integrated, showing improved immunogenicity and lower virulence.

We have shown here that introduction of the RD1 region makes the vaccine strains induce a more effective immune response against a challenge with *M. tuberculosis*.

However, this first generation of constructs can be followed by other, more fine-tuned generations of constructs as the complemented BCG::RD1 vaccine strain also showed a more virulent phenotype in severely immuno-compromised (SCID) mice. Therefore, the BCG RD1+ constructs may be modified to as to be applicable as vaccine strains while being safe for immuno-compromised individuals.

[0023] In this perspective, the man skilled in the art can adapt the BCG::RD1 strain by the conception of BCG vaccine strains that only carry parts of the genes coding for ESAT-6 or CFP-10 in a mycobacterial expression vector (for example pSM81) under the control of a promoter, more particularly an hsp60 promoter. For example, at least one portion of the esat-6 gene that codes for immunogenic 20-mer peptides of ESAT-6 active as T-cell epitopes (Mustafa AS, Oftung F, Amoudy HA, Madi NM, Abal AT, Shaban F, Rosen Krands I, & Andersen P. (2000) Multiple epitopes from the *Mycobacterium tuberculosis* ESAT-6 antigen are recognized by antigen-specific human T cell lines. *Clin Infect Dis.* 30 Suppl 3:S201-5, peptides P1 to P8 are incorporated herein in the description) could be cloned into this vector and electroporated into BCG, resulting in a BCG strain that produces these epitopes.

[0024] Alternatively, the ESAT-6 and CFP-10 encoding genes (for example on plasmid RD1-AP34 and or RD1-2F9)

could be altered by directed mutagenesis (using for example QuikChange Site-Directed Mutagenesis Kit from Stratagene) in a way that most of the immunogenic peptides of ESAT-6 remain intact, but the biological functionality of ESAT-6 is lost.

This approach could result in a more protective BCG vaccine without increasing the virulence of the recombinant BCG construct.

[0025] Therefore, the invention is also aimed at a method for preparing and selecting *M. bovis* BCG or *M. microti* strains comprising a step consisting of modifying the *M. bovis* BCG::DR1 or *M. microti*::DR1 strains as defined above by insertion, deletion or mutation in the integrated DR1 region, more particularly in the esat-6 or CFP-10 gene, said method leading to strains that are less virulent for immuno-depressed individuals. Together, these methods would allow to explain what causes the effect that we see with our BCG::RD1 strain (the presence of additional T-cell epitopes from ESAT-6 and CFP10 resulting in increased immunogenicity) or whether the effect is caused by better fitness of the recombinant BCG::RD1 clones resulting in longer exposure time of the immune system to the vaccine - or - by a combinatorial effect of both factors.

[0026] In a preferred embodiment, the invention is aimed at the *M. bovis* BCG::RD1 strains, which have integrated a cosmid herein referred to as the RD1-2F9 and RD1-AP34 contained in the *E. coli* strains deposited on April 2, 2002 at the CNCM (Institut Pasteur, 25, rue du Docteur Roux, 75724 Paris cedex 15, France) under the accession number I-2831 and 1-2832 respectively. The RD1-2F9 is a cosmid comprising a portion of the *Mycobacterium tuberculosis* H37Rv genome that spans the RD1 region and the hygromycin resistance gene. The RD1-AP34 is a cosmid comprising a portion of the *Mycobacterium tuberculosis* DNA containing two genes coding for ESAT-6 and CFP-10 as well as a gene conferring resistance to Kanamycin.

[0027] The construct RD1-AP34 contains a 3909 bp fragment of the *M. tuberculosis* H37Rv genome from region 4350459 bp to 4354367 bp cloned into an integrating vector pKint (SEQ ID No 1). The Accession No. of the segment 160 of the *M. tuberculosis* H37Rv genome that contains this region is AL022120.

25

SEQ ID No 1 :

30 1 - gaattccat ccagttagtt caaggtcaag cggcgccccc ctggccaggc atttctcgtc
 61 - tcgccagacg gcaaagaggt catccaggcc ccctacatcg agcctccaga agaagtgttc
 121 - gcagcacccc caagcgccgg ttaagattat ttcattgccg gtgttagcagg acccgagctc
 181 - agcccgtaa tcgagttcgg gcaatgctga ccatcggtt tgttccggc tataaccgaa
 35 241 - cgttttgtt acgggataca aatacaggga gggagaagt aggcaaagg aaaaaaatgtc
 301 - acatgaccg atcgctgccg acatggcac gcaagtgagc gacaacgctc tgcacggcgt
 361 - gacggccggc tcgacggcgc tgacgtcggt gaccgggtg gttcccgccg gggccgatga
 40 421 - ggtcccgcaagaccaggc tccaccgtgc gggcgaagcg gtccaggacg tgcacggcac
 481 - tgcatcgcccaagaccaggc tccaccgtgc gggcgaagcg gtccaggacg tgcacggcac
 541 - ctattcgcaatcgacgacg ggcgcgcccgg cgtcgtcgcc gaataggccc ccaacacatc
 601 - ggaggggatgt atcaccatgc tgtaggcacgc aatgcccaccc gagctaaataccgcacggct

50

55

5 661 - gatggccggc gcgggtccgg ctccaaatgct tcggcgccc gcggatggc agacgcttc
721 - ggcggctctg gacgctcagg ccgtcgagtt gaccgcgcgc ctgaactctc tggagaagc
781 - ctggacttoga ggtggcagcg acaaggcgct tcggctgca acgcccgtgg tggctggct
841 - acaaaccgcg tcaacacagg ccaagaccccg tgcgtatgcag gcgacggcgc aagccgcggc
10 901 - atacacccag gccatggcca cgacgcgcgc gctgccggag atgccgcaca accacatcac
961 - ccaggccgc tttacggcca ccaacttctt cggatcaac acgatcccga tcgcgttgac
1021 - cgagatggat tatttcatcc gttatgtggaa ccaggcagcc ctggcaatgg aggcttacca
15 1081 - ggccgagacc gcggtaaca cgctttcga gaaatcgag ccgtatggcgt cgatccttga
1141 - tcccgccgcg agccagagca cgacgaaccc gatcttcgga atgccctccc ctggcagcgc
1201 - aacaccgggtt gcccaggatgc cggccggcgc tacccagacc ctggcccaac tgggtgagat
20 1261 - gagcggcccg aitcagcagc tgacccagcc gctgcagcag gtgacgtcgt tggcagcca
1321 - ggtgggcggc accggcggcg gcaacccagc cgacgaggaa gccgcgcaga tggcctgct
1381 - cggcaccagt ccgcttcga accatccgc ggcgttggta tcaggccccca gcgcggggcgc
1441 - gggcctgctg cggcggagt cgctacctgg cgcagggtgg tcgttgaccc gcacgcccgc
25 1501 - gatgttcag ctgatcgaaa agccggtgc cccctcggt atgccggcgg ctgtgcgg
1561 - atcgtcggcg acgggtggcg ccgctccgg ggttcggga gcgtatggcc agggtgcgca
1621 - atccggcggc tccaccaggc cgggttcgtt cgccggca ccgcgcgcgc aggagcgtga
30 1681 - agaagacgac gaggacgact gggacgaaga ggacgactgg tgagctcccg taatgacaac
1741 - agacttcccg gccacccggg ccggaagact tgccaaacatt ttggcgagga aggtaaagag
1801 - agaaaatgtt ccagcatggc agagatgaag accgatgccg ctaccctcgc gcaggaggca
35 1861 - ggtaatttcg agcggatctc cggcgacctg aaaacccaga tcgaccagggt ggagtcgacg
1921 - gcaggttcgt tgcaggccca gtggcgccgc gggcggggca cggccggccca ggccgcgggt
40 1981 - gtgegttcc aagaagcagc caataagcag aagcaggaac tcgacgagat ctgcacgaat
2041 - atcgtcagg ccggcggtcca atactcgagg gccgacgagg agcagcagca ggccgtgtcc
2101 - tcgcaaatgg gtttcgtacc cgctaaatcg aaaagaaacg gagcaaaaac aitcagcagc
45 2161 - agcagtgaa ttgcgggtt atcgaggccg cggcaagcgc aatccaggaa aatgtcacgt
2221 - ccatccatcc ctcccttgc gggggggc agtccctgac caagctcgca gcggccgggg
2281 - gcggtaacgg ttcggggccg taccatgggtt tccatggcaaaa atggggacgcgc acggcttcc

2341 - agctgaacaa cgcgctgcag aaccggcgcc gagatcg cgaagccgtt caggcaatgg
 5 2401 - cttcgaccga aggcaacgtc actggatgt tcgcataagg caacgccgag ttgcgtaga
 2461 - atagcgaaac acgggatcg ggagatcg cttccgtcg gtctgcctt ttcgtgtt
 10 2521 - tatacgttt agcgcactt gagagggtgtt catggcggcc gactacgaca agctttccg
 2581 - gccgcacgaa ggtatggaag ctccggacga tatggcagcg cagccgtct tcgaccccg
 2641 - tgcttcgttt ccggccggcgc ccgcattcgcc aaacctaccg aagcccaacg gccagaccc
 15 2701 - gcccccgacg tccgacgacc tgcggagcg gttcgtgtcg gccccggcgc cgccacccccc
 2761 - acccccaccc ccgcctccgc caactccgtat ggcgtcgcc gcaggagagc cgccctcgcc
 2821 - ggaaccggcc gcatctaaac caccacacc ccccatgccc atgcgggac ccgaaccggc
 2881 - cccacccaaa ccacccacac ccccatgcc catggccgga cccgaaccgg cccacccaa
 2941 - accacccaca cctccgatgc ccatgcggg acctgcaccc accccaaccc aatccagtt
 3001 - ggcgcaccc agaccaccga caccacaaac gccaaccgga ggcgcgcgc aaccggaaatc
 3061 - accggcgccc cacgtaccct cgcacgggccc acatcaaccc cggcgacccg caccaggacc
 25 3121 - gcccggca aagatgcca tcggcgaacc cccggccgtt ccgtccagac cgtctgcgtc
 3181 - cccggccgaa ccaccgaccc ggcctgcccc ccaacactcc cgacgtgcgc gccggggta
 3241 - ccgtatgc acagacacccg aacgaaacgtt cggaaaggta gcaactggtc catccatcca
 3301 - ggcgcggctg cggcagagg aagcatccgg cgcgcagc cccggggaa cggagccctc
 3361 - ggcgcgcgg tggggccaa ctagatgcgtatggctccg cccacccggcc cggcgccgac
 3421 - agaacctccc cccagccct cgcgcagcg caacccgtt cggcgccgc agcgacgcgt
 3481 - ccacccgtt tagccgccc aacatgcgc ggcgcaacctt gatcaattt cggccgcaac
 3541 - cactggcggtt cgtcgccgca agcgatgcgc gccggatctc gacgcgacac agaaatcc
 3601 - aaggccggcg gccaaggggc cgaagggtt gaaaggtaag cccagaaac cgaaggccac
 3661 - gaagccgccc aaagtgggtt cgcagcgccg ctggcgacat tgggtgcattt cggtgcgc
 40 3721 - aatcaaccgtt ggcctgtcac ccgacgagaa gtacgagctt gacctgcacg ctcgagtc
 3781 - ccgcaatccc cgggggtgtt atcagatgcgc cgtcgccgtt cccaaagggtt gggctggca
 3841 - aaccacgcgtt acagcagcggtt tgggtcgac gttggctcag gtgcggccgc accggatcc
 45 3901 - ggctctaga

50

pos. 0001-0006 EcoRI-restriction site

pos. 0286-0583 *Rv3872 coding for a PE-Protein* (SEQ ID No 2)

55

pos. 0616-1720 *Rv3873 coding for a PPE-Protein* (SEQ ID No 3)

pos. 1816-2115 *Rv3874* coding for Culture Filtrat protein 10kD (CFP10) (SEQ ID No 4)

5

pos. 2151-2435 *Rv3875* coding for Early Secreted Antigen Target 6kD (ESAT6) (SEQ ID No 5)

10

pos. 3903-3609 **XbaI-restriction site**

pos. 1816-2435 CFP-10 gene + esat-6 gene (SEQ ID No 6)

15

[0028] The sequence of the fragment RD1-2F9 (~ 32 kb) covers the region of the *M. tuberculosis* genome AL123456 from ca 4337 kb to ca. 4369 kb, and also contains the sequence described above.

[0029] Such strains fulfill the aim of the invention which is to provide an improved tuberculosis vaccine or *M. bovis* BCG-based prophylactic or therapeutic agent, or a recombinant *M. microti* derivative for these purposes.

[0030] The above described *M. bovis* BCG::RD1 strains are better tuberculosis vaccines than *M. bovis* BCG. These strains can also be improved by reintroducing other genes found in the RD8 and RD5 loci of *M. tuberculosis*. These regions code for additional T-cell antigens. As indicated, overexpressing the genes contained in the RD1, RD5 and RD8 regions by means of exogenous promoters is encompassed by the invention. The same applies regarding *M. microti*::RD1 strains. *M. microti* strains could also be improved by reintroducing the RD8 locus of *M. tuberculosis*.

[0031] In a second embodiment, the invention is directed to a cosmid or a plasmid comprising part or all of the RD1 region originating from *Mycobacterium tuberculosis*, said region comprising at least one gene selected from Rv3871, Rv3872 (mycobacterial PE), Rv3873 (PPE), Rv3874 (CFP-10), Rv3875 (ESAT-6), and Rv3876. Preferably, such cosmids or plasmid comprises CFP-10, ESAT-6 or both. The invention also relates to the use of these cosmids or plasmids for transforming *M. bovis* BCG or *M. microti* strains. As indicated above, these cosmids or plasmids may comprise a mutated gene selected from Rv3871 to Rv3876, said mutated gene being responsible for the improved immunogenicity and decreased virulence.

[0032] In another embodiment, the invention embraces a pharmaceutical composition comprising a strain as depicted above and a pharmaceutically acceptable carrier.

[0033] In addition to the strains, these pharmaceutical compositions may contain suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the living vaccine into preparations which can be used pharmaceutically. Further details on techniques for formulation and administration may be found in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing Co., Easton, Pa.).

[0034] Preferably, such composition is suitable for oral intravenous or subcutaneous administration.

[0035] The determination of the effective dose is well within the capability of those skilled in the art. A therapeutically effective dose refers to that amount of active ingredient, i.e the number of strains administered, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in experimental animals, e.g., ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD50/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. Of course, ED50 is to be modulated according to the mammal to be treated or vaccinated. In this regard, the invention contemplates a composition suitable for human administration as well as veterinary composition.

[0036] The invention is also aimed at a vaccine comprising a *M. bovis* BCG::RD1 or *M. microti*::RD1 strain as depicted above and a suitable carrier. This vaccine is especially useful for preventing tuberculosis. It can also be used for treating bladder cancer.

[0037] The invention also concerns a product comprising a strain as depicted above and at least one protein selected from ESAT-6 and CFP-10 or epitope derived thereof for a separate, simultaneous or sequential use for treating tuberculosis.

[0038] In still another embodiment, the invention concerns the use of a *M. bovis* BCG::RD1 or *M. microti*::RD1 strain as depicted above for preventing or treating tuberculosis.

It also concerns the use of a *M. bovis* BCG::RD1 or *M. microti*::RD1 strain as a powerful adjuvant/immunomodulator used in the treatment of superficial bladder cancer.

[0039] The invention also contemplates the identification at the species level of members of the *M. tuberculosis*

complex by means of an RD-based molecular diagnostic test. Inclusion of markers for RD1^{mic} and RD5^{mic} would improve the tests and act as predictors of virulence, especially in humans. In this regard, the invention concerns a diagnostic kit comprising DNA probes and primers specifically hybridizing to a DNA portion of the RD1 or RD5 region, more particularly probes hybridizing under stringent conditions to a gene selected from Rv3871, Rv3872 (mycobacterial PE), Rv3873 (PPE), Rv3874 (CFP-10), Rv3875 (ESAT-6), and Rv3876, preferably CFP-10 and ESAT-6. As used herein, the term "stringent conditions" refers to conditions which permit hybridization between the probe sequences and the polynucleotide sequence to be detected. Suitably stringent conditions can be defined by, for example, the concentrations of salt or formamide in the prehybridization and hybridization solutions, or by the hybridization temperature, and are well known in the art. In particular, stringency can be increased by reducing the concentration of salt, increasing the concentration of formamide, or raising the hybridization temperature. The temperature range corresponding to a particular level of stringency can be further narrowed by calculating the purine to pyrimidine ratio of the nucleic acid of interest and adjusting the temperature accordingly. Variations on the above ranges and conditions are well known in the art.

15 [0040] Among the preferred primers, we can cite:

primer esat-6F GTCACGTCCATTCAATTCCCT (SEQ ID No 9),

20 primer esat-6R ATCCCAGTGACGTTGCCTT (SEQ ID No 10),

25 primer RD1^{mic} flanking region F GCAGTGCAAAGGTGCAGATA (SEQ ID No 11),

primer RD1^{mic} flanking region R GATTGAGACACTTGCACGA (SEQ ID No 12),

30 primer RD5^{mic} flanking region F GAATGCCGACGTCATATCG (SEQ ID No 16),

35 primer RD5^{mic} flanking region R CGGCCACTGAGTCGATTAT (SEQ ID No 17).

[0041] The present invention covers also the complementary nucleotidic sequences of said above primers as well as the nucleotidic sequences hybridizing under stringent conditions with them and having at least 20 nucleotides and less than 500 nucleotides.

[0042] Diagnostic kits for the identification at the species level of members of the *M. tuberculosis* comprising antibodies directed to mycobacterial PE, PPE, CFP-10 and ESAT-6 are also embraced by the invention. As used herein, the term "antibody" refers to intact molecules as well as fragments thereof, such as Fab, F(ab').sub.2, and Fv, which are capable of binding the epitopic determinant. Probes or antibodies can be labeled with isotopes, fluorescent or phosphorescent molecules or by any other means known in the art.

[0043] The invention is further detailed below and will be illustrated with the following figures.

45 Figure legends

[0044]

50 **Figure 1: *M. bovis* BCG and *M. microti* have a chromosomal deletion, RD1, spanning the *cfp10-esat6* locus.**

(A) Map of the *cfp10-esat6* region showing the six possible reading frames and the *M. tuberculosis* H37Rv gene predictions. This map is also available at: (<http://genolist.pasteur.fr/TubercuList/>).

The deleted regions are shown for BCG (red) and *M. microti* (blue) with their respective H37Rv genome coordinates, and the extent of the conserved ESAT-6 locus (F. Tekaia, et al., *Tubercle Lung Disease* 79, 329 (1999)), is indicated by the gray bar.

(B) Table showing characteristics of deleted regions selected for complementation analysis. Potential virulence factors and their putative functions disrupted by each deletion are shown. The coordinates are for the *M.*

tuberculosis H37Rv genome.

(C) Clones used to complement BCG. Individual clones spanning RD1 regions (RD1-I106 and RD1-2F9) were selected from an ordered *M. tuberculosis* genomic library (R.B. unpublished) in pYUB412 (S. T. Cole, *et al.*, *Nature* **393**, 537 (1998) and W. R. Bange, F. M. Collins, W. R. Jacobs, Jr., *Tuber. Lung Dis.* **79**, 171 (1999)) and electroporated into *M. bovis* BCG strains, or *M. microti*. Hygromycin-resistant transformants were verified using PCR specific for the corresponding genes. pAP35 was derived from RD1-2F9 by excision of an *Afl*I fragment. pAP34 was constructed by subcloning an *Eco*RI-*Xba*I fragment into the integrative vector pKINT. The ends of each fragment are related to the BCG RD1 deletion (shaded box) with black lines and the H37Rv coordinates for the other fragment ends given in kilobases.

(D) Immunoblot analysis, using an ESAT-6 monoclonal antibody, of whole cell protein extracts from log-phase cultures of H37Rv (S. T. Cole, *et al.*, *Nature* **393**, 537 (1998)), BCG::pYUB412 (M. A. Behr, *et al.*, *Science* **284**, 1520 (1999)), BCG::RD1-I106 (R. Brosch, *et al.*, *Infection Immun.* **66**, 2221 (1998)), BCG::RD1-2F9 (S. V. Gordon, *et al.*, *Molec Microbiol* **32**, 643 (1999)), *M. bovis* (H. Salamon et al, *Genome Res* **10**, 2044 (2000)), *Mycobacterium smegmatis* (G. G. Mahairas, *et al.*, *J. Bacteriol.* **178**, 1274 (1996)), *M. smegmatis*::pYUB412, and *M. smegmatis*:: RD1-2F9 (R. Brosch, *et al.*, *Proc Natl Acad Sci USA* **99**, 3684 (2002)).

Figure 2: Complementation of BCG Pasteur with the RD1 region alters the colony morphology and leads to accumulation of Rv3873 and ESAT-6 in the cell wall.

(A) Serial dilutions of 3 week old cultures of BCG::pYUB412, BCG::I106 or BCG::RD1-2F9 growing on Middlebrook 7H10 agar plates. The white square shows the area of the plate magnified in the image to the right.

(B) Light microscope image at fifty fold magnification of BCG::pYUB412 and BCG::RD1-2F9 colonies. 5 μ l drops of bacterial suspensions of each strain were spotted adjacently onto 7H10 plates and imaged after 10 days growth, illuminating the colonies through the agar.

(C) Immunoblot analysis of different cell fractions of H37Rv obtained from <http://www.cvmbs.colostate.edu/microbiology/tb/ResearchMA.html> using either an anti-ESAT-6 antibody or

(D) anti-Rv3873 (PPE) rabbit serum. H37Rv and BCG signify whole cell extracts from the respective bacteria and Cyt, Mem and CW correspond to the cytosolic, membrane and cell wall fractions of *M. tuberculosis* H37Rv.

Figure 3: Complementation of BCG Pasteur with the RD1 region increases bacterial persistence and pathogenicity in mice.

(A) Bacteria in the spleen and lungs of BALB/c mice following intravenous (i.v.) infection via the lateral tail vein with 10^6 colony forming units (cfu) of *M. tuberculosis* H37Rv (red) or 10^7 cfu of either BCG::pYUB412 (yellow) or BCG::RD1-I106 (green).

(B) Bacterial persistence in the spleen and lungs of C57BL/6 mice following i.v. infection with 10^5 cfu of BCG::pYUB412 (yellow), BCG::RD1-I106 (green) or BCG::RD1-2F9 (blue).

(C) Bacterial multiplication after i.v. infection with 10^6 cfu of BCG::pYUB412 (yellow) and BCG::RD1-2F9 (blue) in severe combined immunodeficiency mice (SCID). For A, B, and C each timepoint is the mean of 3 to 4 mice and the error bars represent standard deviations.

(D) Spleens from SCID mice three weeks after i.v. infection with 10^6 cfu of either BCG::pYUB412, BCG::RD1-2F9 or BCG::I301 (an RD3 "knock-in", Fig. 1B). The scale is in cm.

Figure 4: Immunisation of mice with BCG::RD1 generates marked ESAT-6 specific T-cell responses and enhanced protection to a challenge with *M. tuberculosis*.

(A) Proliferative response of splenocytes of C57BL/6 mice immunised subcutaneously (s.c.) with 10^6 CFU of BCG::pYUB412 (open squares) or BCG::RD1-2F9 (solid squares) to *in vitro* stimulation with various concentrations of synthetic peptides from poliovirus type 1 capsid protein VP1, ESAT-6 or Ag85A (K. Huygen, *et al.*, *Infect. Immun.* **62**, 363 (1994), L. Brandt, *J. Immunol.* **157**, 3527 (1996) and C. Leclerc et al, *J. Virol.* **65**, 711

(1991)).

5 (B) Proliferation of splenocytes from BCG::RD1-2F9-immunised mice in the absence or presence of 10 µg/ml of ESAT-6 1-20 peptide, with or without 1 µg/ml of anti-CD4 (GK1.5) or anti-CD8 (H35-17-2) monoclonal antibody. Results are expressed as mean and standard deviation of 3 H-thymidine incorporation from duplicate wells.

10 (C) Concentration of IFN- γ in culture supernatants of splenocytes of C57BL/6 mice stimulated for 72 h with peptides or PPD after s.c. or i.v. immunisation with either BCG::pYUB412 (red and yellow) or BCG::RD1-2F9 (green and blue). Mice were inoculated with either 10^6 (yellow and green) or 10^7 (red and blue) cfu. Levels of IFN- γ were quantified using a sandwich ELISA (detection limit of 500 pg/ml) with the mAbs R4-6A2 and biotin-conjugated XMG1.2. Results are expressed as the mean and standard deviation of duplicate culture wells.

15 (D) Bacterial counts in the spleen and lungs of vaccinated and unvaccinated BALB/c mice 2 months after an i.v. challenge with *M. tuberculosis* H37Rv. The mice were challenged 2 months after i.v. inoculation with 10^6 cfu of either BCG::pYUB412 or BCG::RD1-2F9. Organ homogenates for bacterial enumeration were plated on 7H11 medium, with or without hygromycin, to differentiate *M. tuberculosis* from residual BCG colonies. Results are expressed as the mean and standard deviation of 4 to 5 mice and the levels of significance derived using the Wilcoxon rang sum test.

20 **Figure 5:** *Mycobacterium microti* strain OV254 BAC map (named MiXXX), overlaid on the *M. tuberculosis* H37Rv (named RvXXX) and *M. bovis* AF2122/97 (named MbXXX) BAC maps. The scale bars indicate the position on the *M. tuberculosis* genome.

25 **Figure 6:** Difference in the region 4340-4360 kb between the deletion in BCG RD1^{bcg} (A) and in *M. microti* RD1^{mic} (C) relatively to *M. tuberculosis* H37Rv (B).

30 **Figure 7:** Difference in the region 3121-3127 kb between *M. tuberculosis* H37Rv (A) and *M. microti* OV254 (B). Gray boxes picture the direct repeats (DR), black ones the unique numbered spacer sequences. * spacer sequence identical to the one of spacer 58 reported by van Embden *et al.* (42). Note that spacers 33-36 and 20-22 are not shown because H37Rv lacks these spacers.

35 **Figure 8:** A) Agarose PFGE profiles of various *M. microti* strains; Hybridization with a radiolabeled B) esat-6 probe; C) probe of the RD1^{mic} flanking region; D) pICa probe. 1. *M. bovis* AF2122/97, 2. *M. canetti*, 3. *M. bovis* BCG Pasteur, 4. *M. tuberculosis* H37Rv, 5. *M. microti* OV254, 6. *M. microti* Myc 94-2272, 7. *M. microti* B3 type mouse, 8. *M. microti* B4 type mouse, 9. *M. microti* B2 type llama, 10. *M. microti* B1 type llama, 11. *M. microti* ATCC 35782. M: Low range PFGE marker (NEB).

40 **Figure 9:** PCR products obtained from various *M. microti* strains using primers that flank the RD1^{mic} region, for amplifying ESAT-6 antigen, that flank the MiD2 region. 1. *M. microti* B1 type llama, 2. *M. microti* B4 type mouse, 3. *M. microti* B3 type mouse, 4. *M. microti* B2 type llama, 5. *M. microti* ATCC 35782, 6. *M. microti* OV254, 7. *M. microti* Myc 94-2272, 8. *M. tuberculosis* H37Rv.

45 **Example 1: preparation and assessment of *M. bovis* BCG::RD1 strains as a vaccine for treating or preventing tuberculosis.**

50 [0045] As mentioned above, we have found that complementation with RD1 was accompanied by a change in colonial appearance as the BCG Pasteur "knock-in" strains developed a strikingly different morphotype (Fig. 2A). The RD1 complemented strains adopted a spreading, less-rugose morphology, that is characteristic of *M. bovis*, and this was more apparent when the colonies were inspected by light microscopy (Fig. 2B). Maps of the clones used are shown (Fig. 1C). These changes were seen following complementation with all of the RD1 constructs (Fig. 1C) and on complementing *M. microti* (data not shown). Pertinently, Calmette and Guérin (A. Calmette, *La vaccination preventive contre la tuberculose*. (Masson et cie., Paris, 1927)) observed a change in colony morphology during their initial passaging of *M. bovis*, and our experiments now demonstrate that this change, corresponding to loss of RD1, directly contributed to attenuating this virulent strain. The integrity of the cell wall is known to be a key virulence determinant for *M. tuberculosis* (C. E. Barry, *Trends Microbiol* 9, 237 (2001)), and changes in both cell wall lipids (M. S. Glickman, J. S. Cox, W. R. Jacobs, Jr., *Mol Cell* 5, 717 (2000)) and protein (F. X. Berhet, *et al.*, *Science* 282, 759 (1998)) have been shown to alter colony morphology and diminish persistence in animal models.

[0046] To determine which genes were implicated in these morphological changes, antibodies recognising three RD1 proteins (Rv3873, CFP10 and ESAT-6) were used in immunocytochemical and subcellular fractionation analysis. When the different cell fractions from *M. tuberculosis* were immunoblotted all three proteins were localized in the cell wall fraction (Fig. 2C) though significant quantities of Rv3873, a PPE protein, were also detected in the membrane and cytosolic fractions (Fig. 2D). Using immunogold staining and electron microscopy the presence of ESAT-6 in the envelope of *M. tuberculosis* was confirmed but no alteration in capsular ultrastructure could be detected (data not shown). Previously, CFP-10 and ESAT-6 have been considered as secreted proteins (F. X. Berhet et al, *Microbiology* 144, 3195 (1998)) but our results suggest that their biological functions are linked directly with the cell wall.

[0047] Changes in colonial morphology are often accompanied by altered bacterial virulence. Initial assessment of the growth of different BCG::RD1 "knock-ins" in C57BL/6 or BALB/c mice following intravenous infection revealed that complementation did not restore levels of virulence to those of the reference strain *M. tuberculosis* H37Rv (Fig. 3A). In longer-term experiments, modest yet significant differences were detected in the persistence of the BCG::RD1 "knock-ins" in comparison to BCG controls. Following intravenous infection of C57BL/6 mice, only the RD1 "knock-ins" were still detectable in the lungs after 106 days (Fig. 3B). This difference in virulence between the RD1 recombinants and the BCG vector control was more pronounced in severe combined immunodeficiency (SCID) mice (Fig. 3C). The BCG::RD1 "knock-in" was markedly more virulent, as evidenced by the growth rate in lungs and spleen and also by an increased degree of splenomegaly (Fig. 3D). Cytological examination revealed numerous bacilli, extensive cellular infiltration and granuloma formation. These increases in virulence following complementation with the RD1 region, demonstrate that the loss of this genomic locus contributed to the attenuation of BCG.

[0048] The inability to restore full virulence to BCG Pasteur was not due to instability of our constructs nor to the strain used (data not shown). Essentially identical results were obtained on complementing BCG Russia, a strain less passaged than BCG Pasteur and presumed, therefore, to be closer to the original ancestor (M. A. Behr, et al., *Science* 284, 1520 (1999)). This indicates that the attenuation of BCG was a polymutational process and loss of residual virulence for animals was documented in the late 1920s (T. Oettinger, et al, *Tuber Lung Dis* 79, 243 (1999)). Using the same experimental strategy, we also tested the effects of complementing with RD3-5, RD7 and RD9 (S. T. Cole, et al., *Nature* 393, 537 (1998); M. A. Behr, et al., *Science* 284, 1520 (1999); R. Brosch, et al., *Infection Immun.* 66, 2221 (1998) and S. V. Gordon et al., *Molec Microbiol* 32, 643 (1999)) encoding putative virulence factors (Fig. 1B). Reintroduction of these regions, which are not restricted to avirulent strains, did not affect virulence in immunocompetent mice. Although it is possible that deletion effects act synergistically it seems more plausible that other attenuating mechanisms are at play.

[0049] Since RD1 encodes at least two potent T-cell antigens (R. Colangelli, et al., *Infect. Immun.* 68, 990 (2000), M. Harboe, et al., *Infect. Immun.* 66, 717 (1998) and R. L. V. Skjøt, et al., *Infect. Immun.* 68, 214 (2000)), we investigated whether its restoration induced immune responses to these antigens or even improved the protective capacity of BCG. Three weeks following either intravenous or subcutaneous inoculation with BCG::RD1 or BCG controls, we observed similar proliferation of splenocytes to an Ag85A (an antigenic BCG protein) peptide (K. Huygen, et al., *Infect. Immun.* 62, 363 (1994)), but not against a control viral peptide (Fig. 4A). Moreover, BCG::RD1 generated powerful CD4⁺ T-cell responses against the ESAT-6 peptide as shown by splenocyte proliferation (Fig. 4A, B) and strong IFN- γ production (Fig. 4C). In contrast, the BCG::pYUB412 control did not stimulate ESAT-6 specific T-cell responses thus indicating that these were mediated by the RD1 locus. ESAT-6 is, therefore, highly immunogenic in mice in the context of recombinant BCG.

[0050] When used as a subunit vaccine, ESAT-6 elicits T-cell responses and induces levels of protection weaker than but akin to those of BCG (L. Brandt et al, *Infect. Immun.* 68, 791 (2000)). Challenge experiments were conducted to determine if induction of immune responses to BCG::RD1-encoded antigens, such as ESAT-6, could improve protection against infection with *M. tuberculosis*. Groups of mice inoculated with either BCG::pYUB412 or BCG::RD1 were subsequently infected intravenously with *M. tuberculosis* H37Rv. These experiments showed that immunisation with the BCG::RD1 "knock-in" inhibited the growth of *M. tuberculosis* within both BALB/c (Fig. 4D) and C57BL/6 mice when compared to inoculation with BCG alone.

[0051] Although the increases in protection induced by BCG::RD1 and the BCG control are modest they demonstrate convincingly that genetic differences have developed between the live vaccine and the pathogen which have weakened the protective capacity of BCG. This study therefore defines the genetic basis of a compromise that has occurred, during the attenuation process, between loss of virulence and reduced protection (M. A. Behr, P. M. Small, *Nature* 389, 133 (1997)). The recombinant BCGs presented here may not be appropriate in their current form as vaccine candidates because of uncertainty about their safety. However, the strategy of reintroducing, or even overproducing (M. A. Horwitz et al, *Proc Natl Acad Sci U S A* 97, 13853 (2000)), the missing immunodominant antigens of *M. tuberculosis* in BCG, could be combined with an immuno-neutral attenuating mutation to create a more efficacious tuberculosis vaccine.

Example 2: BAC based comparative genomics identifies *Mycobacterium microti* as a natural ESAT-6 deletion mutant.

[0052] We searched for any genetic differences between human and vole isolates that might explain their different degree of virulence and host preference and what makes the vole isolates harmless for humans. In this regard, comparative genomics methods were employed in connection with the present invention to identify major differences that may exist between the *M. microti* reference strain OV254 and the entirely sequenced strains of *M. tuberculosis* H37Rv (10) or *M. bovis* AF2122/97 (14). An ordered Bacterial Artificial Chromosome (BAC) library of *M. microti* OV254 was constructed and individual BAC to BAC comparison of a minimal set of these clones with BAC clones from previously constructed libraries of *M. tuberculosis* H37Rv and *M. bovis* AF2122/97 was undertaken.

Ten regions were detected in *M. microti* that were different to the corresponding genomic regions in *M. tuberculosis* and *M. bovis*. To investigate if these regions were associated with the ability of *M. microti* strains to infect humans, their genetic organization was studied in 8 additional *M. microti* strains, including those isolated recently from patients with pulmonary tuberculosis. This analysis identified some regions that were specifically absent from all tested *M. microti* strains, but present in all other members of the *M. tuberculosis* complex and other regions that were only absent from vole isolates of *M. microti*.

2.1 MATERIALS AND METHODS

[0053] **Bacterial strains and plasmids.** *M. microti* OV254 which was originally isolated from voles in the UK in the 1930's was kindly supplied by MJ Colston (45). DNA from *M. microti* OV216 and OV183 were included in a set of strains used during a multicenter study (26). *M. microti* Myc 94-2272 was isolated in 1988 from the perfusion fluid of a 41-year-old dialysis patient (43) and was kindly provided by L. M. Parsons. *M. microti* 35782 was purchased from American Type Culture Collection (designation TMC 1608 (M.P. Prague)). *M. microti* B1 type llama, B2 type llama, B3 type mouse and B4 type mouse were obtained from the collection of the National Reference Center for Mycobacteria, Forschungszentrum Borstel, Germany. *M. bovis* strain AF2122/97, spoligotype 9 was responsible for a herd outbreak in Devon in the UK and has been isolated from lesions in both cattle and badgers. Typically, mycobacteria were grown on 7H9 Middlebrook liquid medium (Difco) containing 10% oleic-acid-dextrose-catalase (Difco), 0.2 % pyruvic acid and 0.05% Tween 80.

[0054] **Library construction, preparation of BAC DNA and sequencing reactions.** Preparation of agarose-cmbedded genomic DNA from *M. microti* strain OV254, *M. tuberculosis* H37Rv, *M. bovis* BCG was performed as described by Brosch et al. (5). The *M. microti* library was constructed by ligation of partially digested *Hind*III fragments (50-125 kb) into pBeloBAC11. From the 10,000 clones that were obtained, 2,000 were picked into 96 well plates and stored at -80°C. Plasmid preparations of recombinant clones for sequencing reactions were obtained by pooling eight copies of 96 well plates, with each well containing an overnight culture in 250 µl 2YT medium with 12.5 µg.ml⁻¹ chloramphenicol. After 5 min centrifugation at 3000 rpm, the bacterial pellets were resuspended in 25 µl of solution A (25 mM Tris, pH 8.0, 50 mM glucose and 10 mM EDTA), cells were lysed by adding 25 µl of buffer B (NaOH 0.2 M, SDS 0.2%). Then 20 µl of cold 3 M sodium acetate pH 4.8 were added and kept on ice for 30 min. After centrifugation at 3000 rpm for 30 min, the pooled supernatants (140 µl) were transferred to new plates. 130 µl of isopropanol were added, and after 30 min on ice, DNA was pelleted by centrifugation at 3500 rpm for 15 min. The supernatant was discarded and the pellet resuspended in 50 µl of a 10 µg/ml RNase A solution (in Tris 10 mM pH 7.5 /EDTA 10 mM) and incubated at 64°C for 15 min. After precipitation (2.5 µl of sodium acetate 3 M pH 7 and 200 µl of absolute ethanol) pellets were rinsed with 200 µl of 70% ethanol, air dried and finally suspended in 20 µl of TE buffer.

[0055] End-sequencing reactions were performed with a *Taq* DyeDeoxy Terminator cycle sequencing kit (Applied Biosystems) using a mixture of 13 µl of DNA solution, 2 µl of Primer (2 µM) (SP6-BAC1, AGTTAGCTCACTCATTAGGCA (SEQ ID No 7), or T7-BAC1, GGATGTGCTGCAAGGCGATTA (SEQ ID No 8)), 2.5 µl of Big Dye and 2.5 µl of a 5X buffer (50 mM MgCl₂, 50 mM Tris). Thermal cycling was performed on a PTC-100 amplifier (MJ Inc.) with an initial denaturation step of 60 s at 95°C, followed by 90 cycles of 15 s at 95°C, 15 s at 56°C, 4 min at 60°C. DNA was then precipitated with 80 µl of 76% ethanol and centrifuged at 3000 rpm for 30 min. After discarding the supernatant, DNA was finally rinsed with 80 µl of 70% ethanol and resuspended in appropriate buffers depending on the type of automated sequencer used (ABI 377 or ABI 3700). Sequence data were transferred to Digital workstations and edited using the TED software from the Staden package (37). Edited sequences were compared against the *M. tuberculosis* H37Rv database (<http://genolist.pasteur.fr/TubercuList/>), the *M. bovis* BLAST server (http://www.sanger.ac.uk/Projects/M_bovis/blast_server.shtml), and in-house databases to determine the relative positions of the *M. microti* OV254 BAC end-sequences.

[0056] **Preparation of BAC DNA from recombinants and BAC digestion profile comparison.** DNA for digestion was prepared as previously described (4). DNA (1 µg) was digested with *Hind*III (Boehringer) and restriction products separated by pulsed-field gel electrophoresis (PFGE) on a Biorad CHEF-DR III system using a 1% (w/v) agarose gel

and a pulse of 3.5 s for 17 h at 6 V.cm⁻¹. Low-range PFGE markers (NEB) were used as size standards. Insert sizes were estimated after ethidium bromide staining and visualization with UV light. Different comparisons were made with overlapping clones from the *M. microti* OV254, *M. bovis* AF2122/97, and *M. tuberculosis* H37Rv pBeloBAC11 libraries.

[0057] **PCR analysis to determine presence of genes in different *M. microti* strains.** Reactions contained 5 µl of 10xPCR buffer (100 mM β-mercaptoethanol, 600 mM Tris-HCl, pH 8.8, 20 mM MgCl₂, 170 mM (NH₄)₂SO₄, 20 mM nucleotide mix dNTP), 2.5 µl of each primer at 2 µM, 10 ng of template DNA, 10% DMSO and 0.5 unit of Taq polymerase in a final volume of 12.5 µl. Thermal cycling was performed on a PTC-100 amplifier (MJ Inc.) with an initial denaturation step of 90 s at 95°C, followed by 35 cycles of 45 s at 95°C, 1 min at 60°C and 2 min at 72°C.

[0058] **RFLP analysis.** In brief, agarose plugs of genomic DNA prepared as previously described (5) were digested with either *Asel*, *Dra*l or *Xba*l (NEB), then electrophoresed on a 1% agarose gel, and finally transferred to Hybond-C extra nitrocellulose membranes (Amersham). Different probes were amplified by PCR from the *M. microti* strain OV254 or *M. tuberculosis* H37Rv using primers for:

esat-6 (esat-6F GTCACGTCCATTCCATTCCCT (SEQ ID No 9);

esat-6R ATCCCAGTGACGTTGCCTT (SEQ ID No 10),

the RD1^{mic} flanking region (4340, 209F GCAGTGCAAAGGTGCAGATA (SEQ ID No 11); 4354, 701R GATTGA-GACACTTGCCACGA (SEQ ID No 12)), or

plcA (plcA.int.F CAAGTTGGGTCTGGTCGAAT (SEQ ID No 13); plcA.int.R GCTACCCAAGGTCTCCTGGT (SEQ ID No 14)). Amplification products were radio-labeled by using the Stratagene Prime-It II kit (Stratagene). Hybridizations were performed at 65°C in a solution containing NaCl 0.8 M, EDTA pH 8, 5 mM, sodium phosphate 50 mM pH 8, 2% SDS, 1X Denhardt's reagent and 100 µg/ml salmon sperm DNA (Genaxis). Membranes were exposed to phosphorimager screens and images were digitalized by using a STORM phospho-imager.

DNA sequence accession numbers. The nucleotide sequences that flank MiD1, MiD2, MiD3 as well as the junction sequence of RD1^{mic} have been deposited in the EMBL database. Accession numbers are AJ345005, AJ345006, AJ315556 and AJ315557, respectively.

2.2 RESULTS

[0059] **Establishment of a complete ordered BAC library of *M. microti* OV254.** Electroporation of pBeloBAC11 containing partial *Hind*III digests of *M. microti* OV254 DNA into *Escherichia coli* DH10B yielded about 10,000 recombinant clones, from which 2,000 were isolated and stored in 96-well plates. Using the complete sequence of the *M. tuberculosis* H37Rv genome as a scaffold, end-sequencing of 384 randomly chosen *M. microti* BAC clones allowed us to select enough clones to cover almost all of the 4.4 Mb chromosome. A few rare clones that spanned regions that were not covered by this approach were identified by PCR screening of pools as previously described (4). This resulted in a minimal set of 50 BACs, covering over 99.9% of the *M. microti* OV254 genome, whose positions relative to *M. tuberculosis* H37Rv are shown in Figure 5. The insert size ranged between 50 and 125 kb, and the recombinant clones were stable. Compared with other BAC libraries from tubercle bacilli (4, 13) the *M. microti* OV254 BAC library contained clones that were generally larger than those obtained previously, which facilitated the comparative genomics approach, described below.

[0060] **Identification of DNA deletions in *M. microti* OV254 relative to *M. tuberculosis* H37Rv by comparative genomics.** The minimal overlapping set of 50 BAC clones, together with the availability of three other ordered BAC libraries from *M. tuberculosis* H37Rv, *M. bovis* BCG Pasteur 1173P2 (5, 13) and *M. bovis* AF2122/97 (14) allowed us to carry out direct BAC to BAC comparison of clones spanning the same genomic regions. Size differences of PFGE-separated *Hind*III restriction fragments from *M. microti* OV254 BACs, relative to restriction fragments from *M. bovis* and/or *M. tuberculosis* BAC clones, identified loci that differed among the tested strains. Size variations of at least 2 kb were easily detectable and 10 deleted regions, evenly distributed around the genome, and containing more than 60 open reading frames (ORFs), were identified. These regions represent over 60 kb that are missing from *M. microti* OV254 strain compared to *M. tuberculosis* H37Rv. First, it was found that phiRv2 (RD11), one of the two *M. tuberculosis* H37Rv prophages was present in *M. microti* OV254, whereas phiRv1, also referred to as RD3 (29) was absent. Second, it was found that *M. microti* lacks four of the genomic regions that were also absent from *M. bovis* BCG. In fact, these four regions of difference named RD7, RD8, RD9 and RD10 are absent from all members of the *M. tuberculosis* complex with the exception of *M. tuberculosis* and *M. canettii*, and seem to have been lost from a common progenitor strain of *M. africanum*, *M. microti* and *M. bovis* (3). As such, our results obtained with individual BAC to BAC comparisons show that *M. microti* is part of this non-*M. tuberculosis* lineage of the tubercle bacilli, and this assumption was further confirmed by sequencing the junction regions of RD7 - RD10 in *M. microti* OV254. The sequences obtained were identical to those from *M. africanum*, *M. bovis* and *M. bovis* BCG strains. Apart from these four conserved regions of difference, and phiRv1 (RD3) *M. microti* OV254 did not show any other RDs with identical junction regions to *M. bovis* BCG Pasteur, which misses at least 17 RDs relative to *M. tuberculosis* H37Rv (1, 13, 35). However, five other regions missing from the genome of *M. microti* OV254 relative to *M. tuberculosis* H37Rv were identified (RD1^{mic}, RD5^{mic}, MiD1, MiD2, MiD3).

Such regions are specific either for strain OV254 or for *M. microti* strains in general. Interestingly, two of these regions, RD1^{mic}, RD5^{mic} partially overlap RDs from the *M. bovis* BCG.

[0061] **Antigens ESAT-6 and CFP-10 are absent from *M. microti*.** One of the most interesting findings of the BAC to BAC comparison was a novel deletion in a genomic region close to the origin of replication (figure 5). Detailed PCR and sequence analysis of this region in *M. microti* OV254 showed a segment of 14 kb to be missing (equivalent to *M. tuberculosis* H37Rv from 4340,4 to 4354,5 kb) that partly overlapped RD1^{bcg} absent from *M. bovis* BCG. More precisely, ORFs Rv3864 and Rv3876 are truncated in *M. microti* OV254 and ORFs Rv3865 to Rv3875 are absent (figure 6). This observation is particularly interesting as previous comparative genomic analysis identified RD1^{bcg} as the only RD region that is specifically absent from all BCG sub-strains but present in all other members of the *M. tuberculosis* complex (1, 4, 13, 29, 35). As shown in Figure 6, in *M. microti* OV254 the RD1^{mic} deletion is responsible for the loss of a large portion of the conserved ESAT-6 family core region (40) including the genes coding for the major T-cell antigens ESAT-6 and CFP-10 (2, 15). The fact that previous deletion screening protocols employed primer sequences that were designed for the right hand portion of the RD1^{bcg} region (i.e. gene Rv3878) (6, 39) explains why the RD1^{mic} deletion was not detected earlier by these investigations. Figure 6 shows that RD1^{mic} does not affect genes Rv3877, Rv3878 and Rv3879 which are part of the RD1^{bcg} deletion.

[0062] **Deletion of phospholipase-C genes in *M. microti* OV254.** RD5^{mic}, the other region absent from *M. microti* OV254, that partially overlapped an RD region from BCG, was revealed by comparison of BAC clone Mi18A5 with BAC Rv143 (figure 5). PCR analysis and sequencing of the junction region revealed that RD5^{mic} was smaller than the RD5 deletion in BCG (Table 1 and 2 below).

TABLE 1.

Description of the putative function of the deleted and truncated ORFs in <i>M. microti</i> OV254			
Region	Start - End	overlapping ORF	Putative Function or family
RD 10	264,5-266,5	Rv0221-Rv0223	<i>echA1</i>
RD 3	1779,5-1788,5	Rv1573-Rv1586	bacteriophage proteins
RD 7	2207,5-2220,5	Rv1964-Rv1977	<i>yrbE3A-3B; mce3A-F; unknown</i>
RD 9	2330-2332	Rv2072-Rv2075	<i>cobL; probable oxidoreductase; unknown</i>
RD5 ^{mic}	2627,6-2633,4	Rv2348-Rv2352	<i>plc A-C; member of PPE family</i>
MiD1	3121,8-3126,6	Rv2816-Rv2819	<i>IS6110 transposase; unknown</i>
MiD2	3554,0-3755,2	Rv3187-Rv3190	<i>IS6110 transposase; unknown</i>
MiD3	3741,1-3755,7	Rv3345-Rv3349	members of the PE-PGRS and PPE families; insertion elements
RD8	4056,8-4062,7	Rv3617-Rv3618	<i>ephA; IpqG; member of the PE-PGRS family</i>
RD1 ^{mic}	4340,4-4354,5	Rv3864-Rv3876	member of the CBXX/CF QX family; member of the PE and PPE families; ESAT-6; CFP10; unknown

TABLE 2. Sequence at the junction of the deleted regions in *M. microti* OV254

Junction	Position	ORFs	Sequences at the junction	Flanking primers
RD1 ^{mic} (SEQ ID No 15)	4340,421- 4354,533	Rv3864- Rv3876	CAAGACGAGGTTGTAACCTCGACG CAGGATCGCGATGAAATGCCAGTCG GCGTCGCTGAGCGCGCGCTGCGCGCG GTCCCATTTCGCTGATTGTTGAACA GCGACGAACCGGTGTTGAAAATGTCGCCT GGGTGGGGATTCCCT	4340,209F (SEQ ID No 11) 4354,701R (SEQ ID No 12) GATTGAGACACTTGCCACGA
RD5 ^{mic} (SEQ ID No 18)	2627,831- 2635,581	Rv2349- Rv2355	CCTCGATGAACCACTGACATGACCC CATCCTTCCAAGAACCTGGAGTCTCC GGACATCCCCGGCGCTCACTGCC CAGGTGTCCCTGGTCGTTCCGTTGACCGT	2627,370F (SEQ ID No 16) GAATGCCGACGTCATATCG 2633,692R (SEQ ID No 17)

			CGAGTCCGAACATCCGTCAATCCGGTGG CAGTCGCTGCGGTGAC	CGGCCACTGAGTCGATTAT
5	MiD1 (SEQ ID No 21)	3121,880- 3126,684	Rv2815c- Rv2818c	CACCTGACATGACCCCCATCCTTCCA AGAACTGGAGTCTCCGGACATGCCGG GGCGGTTCAAGGACATTCACTGCCATCTT CTGGCAGATCAGCAGATCGCTTGTCTCAG TGCAGGTGAGTC
10	MiD2 (SEQ ID No 24)	3554,066- 3555,259	Rv3188- Rv3189	GCTGCCTACTACGGCTAACGCCAGAG ACCAGCCGCCGGCTGAGGTCTCAGAT CAGAGAGTCTCCGGACTCACCGGGGC GGTTCATAAAGGCTTCGAGACCGGACGG GCTGTAGGTTCTCAACTGTGTGGCCGAT GGTCTGAGCACTTAAC
15	MiD3 (SEQ ID No 27)	3741,139- 3755,777	Rv3345c- Rv3349c	TGGCGCCGGCACCTCCGTGCCACCG TTGCCGCCGCTGGTGGGCCGGTGC GTTCGCCCCGGCCGAACCGTTCAAGG CCGGGTTCGCCCTCAGCCGCTAACACG CCGACCAAGATCAACGAGCTACCTGCCG GTCAAGGTTGAAGAGCCCCCATATCAGCA AGGGCCCGGTGTCGGCG

[0063] In fact, *M. microti* OV254 lacks the genes *plcA*, *plcB*, *plcC* and two specific PPE-protein encoding genes (Rv2352, Rv2353). This was confirmed by the absence of a clear band on a Southern blot of *Asel* digested genomic DNA from *M. microti* OV254 hybridized with a *plcA* probe. However, the genes Rv2346c and Rv2347c, members of the *esal-6* family, and Rv2348c, that are missing from *M. bovis* and BCG strains (3) are still present in *M. microti* OV254. The presence of an IS6110 element in this segment suggests that recombination between two IS6110 elements could have been involved in the loss of RD5^{mic}, and this is supported by the finding that the remaining copy of IS6110 does not show a 3 base-pair direct repeat in strain OV254 (Table 2).

[0064] **Lack of MiD1 provides genomic clue for *M. microti* OV254 characteristic spoligotype.** MiD1 encompasses the three ORFs Rv2816, Rv2817 and Rv2818 that encode putative proteins whose functions are yet unknown, and has occurred in the direct repeat region (DR), a polymorphic locus in the genomes of the tubercle bacilli that contains a cluster of direct repeats of 36 bp, separated by unique spacer sequences of 36 to 41 bp (17), (figure 7). The presence or absence of 43 unique spacer sequences that intercalate the DR sequences is the basis of spacer-oligo typing, a powerful typing method for strains from the *M. tuberculosis* complex (23). *M. microti* isolates exhibit a characteristic spoligotype with an unusually small DR cluster, due to the presence of only spacers 37 and 38 (43). In *M. microti* OV254, the absence of spacers 1 to 36, which are present in many other *M. tuberculosis* complex strains, appears to result from an IS6110 mediated deletion of 636 bp of the DR region. Amplification and *Pvu*II restriction analysis of a 2.8 kb fragment obtained with primers located in the genes that flank the DR region (Rv2813c and Rv2819) showed that there is only one copy of IS6110 remaining in this region (figure 7). This IS6110 element is inserted into ORF Rv2819 at position 3,119,932 relative to the *M. tuberculosis* H37Rv genome. As for other IS6110 elements that result from homologous recombination between two copies (7), no 3 base-pair direct repeat was found for this copy of IS6110 in the DR region. Concerning the absence of spacers 39-43 (figure 7), it was found that *M. microti* showed a slightly different organization of this locus than *M. bovis* strains, which also characteristically lack spacers 39-43. In *M. microti* OV254 an extra spacer of 36 bp was found that was not present in *M. bovis* nor in *M. tuberculosis* H37Rv. The sequence of this specific spacer was identical to that of spacer 58 reported by van Embden and colleagues (42). In their study of the DR region in many strains from the *M. tuberculosis* complex this spacer was only found in *M. microti* strain NLA000016240 (AF189828) and in some ancestral *M. tuberculosis* strains (3, 42). Like MiD1, MiD2 most probably results from an IS6110-mediated deletion of two genes (Rv3188, Rv3189) that encode putative proteins whose function is unknown (Table 2 above and Table 3 below).

TABLE 3.

Presence of the RD and MiD regions in different <i>M. microti</i> strains									
HOST	VOLES					HUMAN			
	Strain	OV 254	OV183	OV216	ATCC	Myc 94	B3	B4 type	B1

TABLE 3. (continued)

Presence of the RD and MiD regions in different <i>M. microti</i> strains										
HOST	VOLES					HUMAN				
	35782	-2272	type mouse	mouse	type llama	type llama				
RD1 ^{mic}	absent	absent	absent	absent	absent	absent	absent	absent	absent	absent
RD 3	absent	absent	absent	absent	absent	absent	absent	absent	absent	absent
RD 7	absent	absent	absent	absent	absent	absent	absent	absent	absent	absent
RD8	absent	absent	absent	absent	absent	absent	absent	absent	absent	absent
RD 9	absent	absent	absent	absent	absent	absent	absent	absent	absent	absent
RD 10	absent	absent	absent	absent	absent	absent	absent	absent	absent	absent
MiD3	absent	ND	ND	absent	absent	absent	absent	absent	absent	absent
MiD1	absent	ND	ND	present	partial	partial	partial	present	present	present
RD5 ^{mic}	absent	absent	absent	present	present	present	present	present	present	present
MiD2	absent	ND	ND	present	present	present	present	present	present	present

ND, not determined

[0065] **Absence of some members of the PPE family in *M. microti*.** MiD3 was identified by the absence of two *Hind*III sites in BAC Mi4B9 that exist at positions 3749 kb and 3754 kb in the *M. tuberculosis* H37Rv chromosome. By PCR and sequence analysis, it was determined that MiD3 corresponds to a 12 kb deletion that has truncated or removed five genes orthologous to Rv3345c-Rv3349c. Rv3347c encodes a protein of 3157 aminoacids that belongs to the PPE family and Rv3346c a conserved protein that is also present in *M. leprae*. The function of both these putative proteins is unknown while Rv3348 and Rv3349 are part of an insertion element (Table 1). At present, the consequences of the MiD3 deletions for the biology of *M. microti* remains entirely unknown.

[0066] **Extra-DNA in *M. microti* OV254 relative to *M. tuberculosis* H37Rv.** *M. microti* OV254 possesses the 6 regions RvD1 to RvD5 and TBDI that are absent from the sequenced strain *M. tuberculosis* H37Rv, but which have been shown to be present in other members of the *M. tuberculosis* complex, like *M. canettii*, *M. africanum*, *M. bovis*, and *M. bovis* BCG (3, 7, 13). In *M. tuberculosis* H37Rv, four of these regions (RvD2-5) contain a copy of IS6110 which is not flanked by a direct repeat, suggesting that recombination of two IS6110 elements was involved in the deletion of the intervening genomic regions (7). In consequence, it seems plausible that these regions were deleted from the *M. tuberculosis* H37Rv genome rather than specifically acquired by *M. microti*. In addition, three other small insertions have also been found and they are due to the presence of an IS6110 element in a different location than in *M. tuberculosis* H37Rv and *M. bovis* AF2122/97. Indeed, *Pvu*II RFLP analysis of *M. microti* OV254 reveals 13 IS6110 elements (data not shown).

[0067] **Genomic diversity of *M. microti* strains.** In order to obtain a more global picture of the genetic organization of the taxon *M. microti* we evaluated the presence or absence of the variable regions found in strain OV254 in eight other *M. microti* strains. These strains which were isolated from humans and voles have been designated as *M. microti* mainly on the basis of their specific spoligotype (26, 32, 43) and can be further divided into subgroups according to the host such as voles, llama and humans (Table 3). As stated in the introduction, *M. microti* is rarely found in humans unlike *M. tuberculosis*. So the availability of 9 strains from variable sources for genetic characterization is an exceptional resource. Among them was one strain (Myc 94-2272) from a severely immuno-compromised individual (43), and four strains were isolated from HIV-positive or HIV-negative humans with spoligotypes typical of llama and mouse isolates. For one strain, ATCC 35872 / M.P. Prague, we could not identify with certainty the original host from which the strain was isolated, nor if this strain corresponds to *M. microti* OV166, that was received by Dr. Sula from Dr. Wells and used thereafter for the vaccination program in Prague in the 1960's (38).

[0068] First, we were interested if these nine strains designated as *M. microti* on the basis of their spoligotypes also resembled each other by other molecular typing criteria. As RFLP of pulsed-field gel separated chromosomal DNA represents probably the most accurate molecular typing strategy for bacterial isolates, we determined the *Asel* profiles of the available *M. microti* strains, and found that the profiles resembled each other closely but differed significantly from the macro-restriction patterns of *M. tuberculosis*, *M. bovis* and *M. bovis* BCG strains used as controls. However, as depicted in Figure 8A, the patterns were not identical to each other and each *M. microti* strain showed subtle differences, suggesting that they were not epidemiologically related. A similar observation was made with other rare cutting restriction enzymes, like *Dra*I or *Xba*I (data not shown).

[0069] **Common and diverging features of *M. microti* strains.** Two strategies were used to test for the presence or absence of variable regions in these strains for which we do not have ordered BAC libraries. First, PCRs using

internal and flanking primers of the variable regions were employed and amplification products of the junction regions were sequenced. Second, probes from the internal portion of variable regions absent from *M. microti* OV254 were obtained by amplification of *M. tuberculosis* H37Rv DNA using specific primers. Hybridization with these radio-labeled probes was carried out on blots from PFGE separated *Asel* restriction digests of the *M. microti* strains. In addition, we 5 confirmed the findings obtained by these two techniques by using a focused macro-array, containing some of the genes identified in variable regions of the tubercle bacilli to date (data not shown).

[0070] **This led to the finding that the RD1^{mic} deletion is specific for all *M. microti* strains tested.** Indeed, none of the *M. microti* DNA-digests hybridized with the radio-labeled *esat-6* probe (Fig. 8B) but with the RD1^{mic} flanking region (Fig. 8C). In addition, PCR amplification using primers flanking the RD1^{mic} region (Table 2) yielded 10 fragments of the same size for *M. microti* strains whereas no products were obtained for *M. tuberculosis*, *M. bovis* and *M. bovis* BCG strains (Fig. 9). Furthermore, the sequence of the junction region was found identical among the strains which confirms that the genomic organization of the RD1^{mic} locus was the same in all tested *M. microti* strains (Table 3). This clearly demonstrates that *M. microti* lacks the conserved ESAT-6 family core region stretching in other members 15 of the *M. tuberculosis* complex from Rv3864 to Rv3876 and, as such, represents a taxon of naturally occurring ESAT-6 / CFP-10 deletion mutants.

[0071] Like RD1^{mic}, MiD3 was found to be absent from all nine *M. microti* strains tested and, therefore, appears to be a specific genetic marker that is restricted to *M. microti* strains (Table 3). However, PCR amplification showed that RD5^{mic} is absent only from the vole isolates OV254, OV216 and OV183, but present in the *M. microti* strains isolated from human and other origins (Table 3). This was confirmed by the presence of single bands but of differing sizes on 20 a Southern blot hybridized with a *plcA* probe for all *M. microti* tested strains except OV254 (Fig. 8D). Interestingly, the presence or absence of RD5^{mic} correlated with the similarity of *IS6110* RFLP profiles. The profiles of the three *M. microti* strains isolated from voles in the UK differed considerably from the *IS6110* RFLP patterns of humans isolates (43). Taken together, these results underline the proposed involvement of *IS6110* mediated deletion of the RD5 region and further suggest that RD5 may be involved in the variable potential of *M. microti* strains to cause disease in humans. 25 Similarly, it was found that MiD1 was missing only from the vole isolates OV254, OV216 and OV183, which display the same spoligotype (43), confirming the observations that MiD1 confers the particular spoligotype of a group of *M. microti* strains isolated from voles. In contrast, PCR analysis revealed that MiD1 is only partially deleted from strains B3 and B4 both characterized by the mouse spoligotype and the human isolate *M. microti* Myc 94-2272 (Table 3). For 30 strain ATCC 35782 deletion of the MiD1 region was not observed. These findings correlate with the described spoligotypes of the different isolates, as strains that had intact or partially deleted MiD1 regions had more spacers present than the vole isolates that only showed spacers 37 and 38.

2.3 COMMENTS AND DISCUSSION

[0072] We have searched for major genomic variations, due to insertion-deletion events, between the vole pathogen, *M. microti*, and the human pathogen, *M. tuberculosis*. BAC based comparative genomics led to the identification of 10 regions absent from the genome of the vole bacillus *M. microti* OV254 and several insertions due to *IS6110*. Seven of 40 these deletion regions were also absent from eight other *M. microti* strains, isolated from voles or humans, and they account for more than 60 kb of genomic DNA. Of these regions, RD1^{mic} is of particular interest, because absence of part of this region has been found to be restricted to the BCG vaccine strains to date. As *M. microti* was originally 45 described as non pathogenic for humans, it is proposed here that RD1 genes is involved in the pathogenicity for humans. This is reinforced by the fact that RD1^{bcg} (29) has lost putative ORFs belonging to the *esat-6* gene cluster including the genes encoding ESAT-6 and CFP-10 (Fig. 6) (40). Both polypeptides have been shown to act as potent stimulators of the immune system and are antigens recognized during the early stages of infection (8, 12, 20, 34). Moreover, the 50 biological importance of this RD1 region for mycobacteria is underlined by the fact that it is also conserved in *M. leprae*, where genes ML0047-ML0056 show high similarities in their sequence and operon organization to the genes in the *esat-6* core region of the tubercle bacilli (11). In spite of the radical gene decay observed in *M. leprae* the *esat-6* operon apparently has kept its functionality in this organism.

[0073] However, the RD1 deletion may not be the only reason why the vole bacillus is attenuated for humans. Indeed, 55 it remains unclear why certain *M. microti* strains included in the present study that show exactly the same RD1^{mic} deletion as vole isolates, have been found as causative agents of human tuberculosis. As human *M. microti* cases are extremely rare, the most plausible explanation for this phenomenon would be that the infected people were particularly susceptible for mycobacterial infections in general. This could have been due to an immunodeficiency (32, 43) or to a rare genetic host predisposition such as interferon gamma- or IL-12 receptor modification (22).

[0074] In addition, the finding that human *M. microti* isolates differed from vole isolates by the presence of region RD5^{mic} may also have an impact on the increased potential of human *M. microti* isolates to cause disease. Intriguingly, BCG and the vole bacillus lack overlapping portions of this chromosomal region that encompasses three (*plcA*, *plcB*, *plcC*) of the four genes encoding phospholipase C (PLC) in *M. tuberculosis*. PLC has been recognized as an important

virulence factor in numerous bacteria, including *Clostridium perfringens*, *Listeria monocytogenes* and *Pseudomonas aeruginosa*, where it plays a role in cell to cell spread of bacteria, intracellular survival, and cytolysis (36, 41). To date, the exact role of PLC for the tubercle bacilli remains unclear. *plcA* encodes the antigen mtp40 which has previously been shown to be absent from seven tested vole and hyrax isolates (28). Phospholipase C activity in *M. tuberculosis*, *M. microti* and *M. bovis*, but not in *M. bovis* BCG, has been reported (21, 47). However, PLC and sphingomyelinase activities have been found associated with the most virulent mycobacterial species (21). The levels of phospholipase C activity detected in *M. bovis* were much lower than those seen in *M. tuberculosis* consistent with the loss of *plcABC*. It is likely, that *plcD* is responsible for the residual phospholipase C activity in strains lacking RD5, such as *M. bovis* and *M. microti* OV254. Indeed, the *plcD* gene is located in region RvD2 which is present in some but not all tubercle bacilli (13, 18). Phospholipase encoding genes have been recognized as hotspots for integration of IS6110 and it appears that the regions RD5 and RvD2 undergo independent deletion processes more frequently than any other genomic regions (44). Thus, the virulence of some *M. microti* strains may be due to a combination of functional phospholipase C encoding genes (7, 25, 26, 29).

[0075] Another intriguing detail revealed by this study is that among the deleted genes seven code for members of the PPE family of Gly-, Ala-, Asn-rich proteins. A closer look at the sequences of these genes showed that in some cases they were small proteins with unique sequences, like for example Rv3873, located in the RD1^{mic} region, or Rv2352c and Rv2353c located in the RD5^{mic} region. Others, like Rv3347c, located in the MiD3 region code for a much larger PPE protein (3157 aa). In this case a neighboring gene (Rv3345c), belonging to another multigene family, the PE-PGRS family, was partly affected by the MiD3 deletion. While the function of the PE/PPE proteins is currently unknown, their predicted abundance in the proteome of *M. tuberculosis* suggests that they may play an important role in the life cycle of the tubercle bacilli. Indeed, recently some of them were shown to be involved in the pathogenicity of *M. tuberculosis* strains (9). Complementation of such genomic regions in *M. microti* OV254 should enable us to carry out proteomics and virulence studies in animals in order to understand the role of such ORFs in pathogenesis.

[0076] In conclusion, this study has shown that *M. microti*, a taxon originally named after its major host *Microtus agrestis*, the common vole, represents a relatively homogenous group of tubercle bacilli. Although all tested strains showed unique PFGE macro-restriction patterns that differed slightly among each other, deletions that were common to all *M. microti* isolates (RD7-RD10, MiD3, RD1^{mic}) have been identified. The conserved nature of these deletions suggests that these strains are derived from a common precursor that has lost these regions, and their loss may account for some of the observed common phenotypic properties of *M. microti*, like the very slow growth on solid media and the formation of tiny colonies. This finding is consistent with results from a recent study that showed that *M. microti* strains carry a particular mutation in the *gyrB* gene (31).

[0077] Of particular interest, some of these common features (e.g. the flanking regions of RD1^{mic}, or MiD3) could be exploited for an easy-to-perform PCR identification test, similar to the one proposed for a range of tubercle bacilli (33). This test enables unambiguous and rapid identification of *M. microti* isolates in order to obtain a better estimate of the overall rate of *M. microti* infections in humans and other mammalian species.

REFERENCES

[0078]

1. Behr, M. A., M. A. Wilson, W. P. Gill, H. Salamon, G. K. Schoolnik, S. Rane, and P. M. Small. 1999. Comparative genomics of BCG vaccines by whole-genome DNA microarray. *Science* **284**:1520-1523.
2. Berthet, F.-X., P. B. Rasmussen, I. Rosenkrands, P. Andersen, and B. Gicquel. 1998. A *Mycobacterium tuberculosis* operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10). *Microbiology* **144**:3195-3203.
3. Brosch, R., S. V. Gordon, M. Marmiesse, P. Brodin, C. Buchrieser, K. Eiglmeier, T. Garnier, C. Gutierrez, G. Hewinson, K. Kremer, L. M. Parsons, A. S. Pym, S. Samper, D. van Soolingen, and S. T. Cole. 2002. A new evolutionary scenario for the *Mycobacterium tuberculosis* complex. *Proc. Natl. Acad. Sci. U S A* **99**:3684-3689.
4. Brosch, R., S. V. Gordon, A. Billault, T. Garnier, K. Eiglmeier, C. Soravito, B. G. Barrell, and S. T. Cole. 1998. Use of a *Mycobacterium tuberculosis* H37Rv bacterial artificial chromosome library for genome mapping, sequencing, and comparative genomics. *Infect. Immun.* **66**:2221-2229.
5. Brosch, R., S. V. Gordon, C. Buchrieser, A. S. Pym, T. Garnier, and S. T. Cole. 2000. Comparative genomics uncovers large tandem chromosomal duplications in *Mycobacterium bovis* BCG Pasteur. *Comp. Funct. Genom. (Yeast)* **17**:111-123.
6. Brosch, R., S. V. Gordon, A. Pym, K. Eiglmeier, T. Garnier, and S. T. Cole. 2000. Comparative genomics of the mycobacteria. *Int. J. Med. Microbiol.* **290**:143-152.
7. Brosch, R., W. J. Philipp, E. Stavropoulos, M. J. Colston, S. T. Cole, and S. V. Gordon. 1999. Genomic analysis reveals variation between *Mycobacterium tuberculosis* H37Rv and the attenuated *M. tuberculosis* H37Ra

strain. *Infect. Immun.* 67:5768-5774.

8. **Brusasca, P. N., R. Colangeli, K. P. Lyashchenko, X. Zhao, M. Vogelstein, J. S. Spencer, D. N. McMurray, and M. L. Gennaro.** 2001. Immunological characterization of antigens encoded by the RD region of the *Mycobacterium tuberculosis* genome. *Scand. J. Immunol.* 54:448-452.

5. **Camacho, L. R., D. Ensergueix, E. Perez, B. Gicquel, and C. Guilhot.** 1999. Identification of a virulence gene cluster of *Mycobacterium tuberculosis* by signature-tagged transposon mutagenesis. *Mol. Microbiol.* 34:257-267.

10. **Cole, S. T., R. Brosch, J. Parkhill, T. Garnier, C. Churcher, D. Harris, S. V. Gordon, K. Eiglmeier, S. Gas, Barry C E III, F. Tekaia, K. Badcock, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. Davies, K. Devlin, T. Feltwell, S. Gentles, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, A. Krogh, J. McLeah, S. Moule, L. Murphy, K. Oliver, J. Osborne, M. A. Quail, M. A. Rajandream, J. Rogers, S. Rutter, K. Soeger, J. Skelton, R. Squares, S. Squares, J. E. Sulston, K. Taylor, S. Whitehead, and B. G. Barrell.** 1998. Deciphering the biology of *Mycobacterium tuberculosis* from the complete genome sequence. *Nature* 393:537-544.

15. **Cole, S. T., K. Eiglmeier, J. Parkhill, K. D. James, N. R. Thomson, P. R. Wheeler, N. Honore, T. Garnier, C. Churcher, D. Harris, K. Mungall, D. Basham, D. Brown, T. Chillingworth, R. Connor, R. M. Davies, K. Devlin, S. Duthoy, T. Feltwell, A. Fraser, N. Hamlin, S. Holroyd, T. Hornsby, K. Jagels, C. Lacroix, J. Maclean, S. Moule, L. Murphy, K. Oliver, M. A. Quail, M. A. Rajandream, K. M. Rutherford, S. Rutter, K. Seeger, S. Simon, M. Simmonds, J. Skelton, R. Squares, S. Squares, K. Stevens, K. Taylor, S. Whitehead, J. R. Woodward, and B. G. Barrell.** 2001. Massive gene decay in the leprosy bacillus. *Nature* 409:1007-1011.

20. **Elhay, M. J., T. Oettinger, and P. Andersen.** 1998. Delayed-type hypersensitivity responses to ESAT-6 and MPT64 from *Mycobacterium tuberculosis* in the guinea pig. *Infect. Immun.* 66:3454-3456.

25. **Gordon, S. V., R. Brosch, A. Billault, T. Garnier, K. Eiglmeier, and S. T. Cole.** 1999. Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. *Mol. Microbiol.* 32:643-655.

30. **Gordon, S. V., K. Eiglmeier, T. Garnier, R. Brosch, J. Parkhill, B. Barrell, S. T. Cole, and R. G. Hewinson.** 2001. Genomics of *Mycobacterium bovis*. *Tuberculosis (Edinb)* 81:157-163.

35. **Harboe, M., A. S. Malin, H. S. Dockrell, H. G. Wiker, G. Ulvund, A. Holm, M. C. Jorgensen, and P. Andersen.** 1998. B-cell epitopes and quantification of the ESAT-6 protein of *Mycobacterium tuberculosis*. *Infect. Immun.* 66:717-723.

40. **Hart, P. D. a., and I. Sutherland.** 1977. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. *British Medical Journal* 2:293-295.

45. **Hermans, P. W. M., D. Van Soolingen, E. M. Bik, P. E. W. De Haas, J. W. Dale, and J. D. A. van Embden.** 1991. Insertion element IS987 from *Mycobacterium bovis* BCG is located in a hot-spot integration region for insertion elements in *Mycobacterium tuberculosis* complex strains. *Infect. Immun.* 59:2695-2705.

50. **Ho, T. B., B. D. Robertson, G. M. Taylor, R. J. Shaw, and D. B. Young.** 2000. Comparison of *Mycobacterium tuberculosis* genomes reveals frequent deletions in a 20 kb variable region in clinical isolates. *Comp. Funct. Genom. (Yeast)* 17:272-282.

55. **Horstkotte, M. A., I. Sobottka, K. Schewe Carl, P. Schaefer, R. Laufs, S. Ruesch-Gerdes, and S. Niemann.** 2001. *Mycobacterium microti* llama-type infection presenting as pulmonary tuberculosis in a human immunodeficiency virus-positive patient. *J. Clin. Microbiol.* 39:406-407.

60. **Horwitz, M. A., B. W. Lee, B. J. Dillon, and G. Harth.** 1995. Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. U S A* 92: 1530-1534.

65. **Johansen, K. A., R. E. Gill, and M. L. Vasin.** 1996. Biochemical and molecular analysis of phospholipase C and phospholipase D activity in mycobacteria. *Infect. Immun.* 64:3259-3266.

70. **Jouanguy, E., R. Doffinger, S. Dupuis, A. Pallier, F. Altare, and J. L. Casanova.** 1999. IL-12 and IFN-gamma in host defense against mycobacteria and salmonella in mice and men. *Curr. Opin. Immunol.* 11:346-351.

75. **Kamerbeek, J., L. Schouls, A. Kolk, M. Van Agterveld, D. Van Soolingen, S. Kuijper, A. Bunschoten, H. Molhuizen, R. Shaw, M. Goyal, and J. Van Embden.** 1997. Simultaneous detection and strain differentiation of *Mycobacterium tuberculosis* for diagnosis and epidemiology. *J. Clin. Microbiol.* 35:907-914.

80. **Kato-Maeda, M., J. T. Rhee, T. R. Gingras, H. Salamon, J. Drenkow, N. Smittipat, and P. M. Small.** 2001. Comparing genomes within the species *Mycobacterium tuberculosis*. *Genome Res.* 11:547-554.

85. **Kremer, K., van Soolingen, D., van Embden, J., Hughes, S., Inwald, J., and G. Hewinson.** 1998. *Mycobacterium microti*: more widespread than previously thought. *J. Clin. Microbiol.* 36:2793-2794.

90. **Kremer, K., D. van Soolingen, R. Frothingham, W. H. Haas, P. W. Hermans, C. Martin, P. Palittapongarnpim, B. B. Plikaytis, L. W. Riley, M. A. Yakrus, J. M. Musser, and J. D. van Embden.** 1999. Comparison of methods based on different molecular epidemiological markers for typing of *Mycobacterium tuberculosis* complex strains: interlaboratory study of discriminatory power and reproducibility. *J. Clin. Microbiol.* 37:2607-2618.

95. **Levy Frebault, V., and F. Portaels.** 1992. Proposed minimal standards for the genus *Mycobacterium* and for description of new slowly growing *Mycobacterium* spp. *Int. J. Syst. Bact.* 42:315-323.

28. **Liebana, E., A. Aranaz, B. Francis, and D. Cousins.** 1996. Assessment of genetic markers for species differentiation within the *Mycobacterium tuberculosis* complex. *J. Clin. Microbiol.* **34**:933-938.

29. **Mahairas, G. G., P. J. Sabo, M. J. Hickey, D. C. Singh, and C. K. Stover.** 1996. Molecular analysis of genetic differences between *Mycobacterium bovis* BCG and virulent *M. bovis*. *J. Bact.* **178**:1274-1282.

5 **Manabe, Y. C., Scott, C. P., and W. R. Bishai.** 2002. Naturally attenuated, orally administered *Mycobacterium microti* as a tuberculosis vaccine is better than subcutaneous *Mycobacterium bovis* BCG. *Infect Immun.* **70**: 1566-1570.

10 **Niemann, S., Harmsen, D., Rusch-Gerdes, S., and E. Richter.** 2000. Differentiation of clinical *Mycobacterium tuberculosis* complex isolates by *gyrB* DNA sequence polymorphism analysis. *J. Clin. Microbiol.* **38**:3231-3234.

15 **Niemann, S., E. Richter, H. Daluegge-Tamm, H. Schlesinger, D. Graupner, B. Koenigstein, G. Gurath, U. Greinert, and S. Ruesch-Gerdes.** 2000. Two cases of *Mycobacterium microti*-derived tuberculosis in HIV-negative immunocompetent patients. *Emerg. Infect. Dis.* **6**:539-542.

20 **Parsons, L. M., Brosch, R., Cole, S. T., Somoskovi, A., Loder, A., Britzel, G., van Soolingen, D., Hale, Y., Salfinger, M.** 2002. Rapid and easy-to-perform identification of *Mycobacterium tuberculosis* complex isolates using PCR-based genomic deletion analysis. *J. Clin. Microbiol.* **submitted** and disclosure of the European Patent Application N° 02 290 458.2 filed on February 25, 2002 (Institut Pasteur).

25 **Rosenkrands, I., P. B. Rasmussen, M. Carnio, S. Jacobsen, M. Theism, and P. Andersen.** 1998. Identification and characterization of a 29-kilodalton protein from *Mycobacterium tuberculosis* culture filtrate recognized by mouse memory effector cells. *Infect. Immun.* **66**:2728-2735.

30 **Salamon, H., M. Kato-Maeda, P. M. Small, J. Drenkow, and T. R. Gingeras.** 2000. Detection of deleted genomic DNA using a semiautomated computational analysis of GeneChip data. *Genome Res.* **10**:2044-2054.

35 **Songer, J. G.**, 1997. Bacterial phospholipases and their role in virulence. *Trends Microbiol.* **5**:156-161.

36 **Staden, R.** 1996. The Staden sequence analysis package. *Mol. Biotechnol.* **5**:233-241.

37 **Sula, L., and I. Radkovsky.** 1976. Protective effects of *M. microti* vaccine against tuberculosis. *J. Hyg. Epid. Microbiol. Immunol.* **20**:1-6.

38 **Talbot, E. A., D. L. Williams, and R. Frothingham.** 1997. PCR identification of *Mycobacterium bovis* BCG. *J. Clin. Microbiol.* **35**:566-569.

39 **Tekaia, F., S. V. Gordon, T. Garnier, R. Brosch, B. G. Barrell, and S. T. Cole.** 1999. Analysis of the proteome of *Mycobacterium tuberculosis* *in silico*. *Tubercle & Lung Disease* **79**:329-342.

40 **Titball, R. W.** 1998. Bacterial phospholipases. *Soc. Appl. Bacteriol. Symp. Ser.* **27**:127-137.

35

40

45

50

55

SEQUENCE LISTING PROVISOIRE

RD1-AP34 (a 3909 bp fragment of the M. tuberculosis H37Rv genome)

5
 gaattcccatccagttagtcaaggtaagcggccccctggccaggcattctcgccagacggcaaa
 gaggtcatccaggccccctacatcgagcctccagaagaagtgtcgacgcaccccaagcgccggttaagattat
 ttcattgccgtgttagcaggaccgagctcagccggtaatcgagttcggcaatgtgaccatcgggttgc
 10
 cggctataaccgaacggtttgtacggatacaatatacaggagggagaagaagttaggaaatggaaaaatgtc
 acatgatccgatcgctgccgacattggcacgcaagttagcgacaaacgctctgcacggcgtgacggccggctcgac
 ggcgtgacgtcggtgaccggctgggtcccggggatgaggtctccgcccagcggcgtacggcgttac
 atcggagggatccaattgtggcttcaatgcattcgcccaagaccagctccaccgtcgccggcgaagcggtcca
 ggacgtcgcccgcaactattcgcaatcgacgacggccggccgttccgcaataggcccccaacacatc
 ggagggagtgtatcaccatgtgtggcacgcaatgccaccggagactaaataccgacggctgatggccggcgg
 tccgctccaatgcttcggccggatggcagacgcttcggccgtctggacgctcaggccgtcaggt
 15
 gaccgcgcgcctgaactctctggagaagcctggactggaggtggcagcgacaaggcgttgcggctgcaacgcc
 gatggtggtctggctacaaaccgcgtcaacacaggccaagaccgtgcgtgcaggcgtacggcgtacggcgg
 atacacccagggccatggccacgacgcgtcgccggagatcggcccaaccacatcaccaggccgttac
 ggccaccaacttctcggtatcaacacgatccgatcgcttgcggccgttacccagaccctcgcccaactgggt
 20
 ggaggcagccctggeaatggaggtctaccaggccagaccgcgttacacgcgtttcgagaagctcgaggccat
 ggcgtcgatcctgtatcccggccgagccagacgacgacgacgatctcggaatgcctccctggcagc
 aacaccgggtggccagttggccggcttccggccgttccggccgttccggccgttccggccgttccggccgtt
 25
 gcaactcgaccaggccgtcgacgcggatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgat
 cgacgaggaagccgcgtatggcctgtcgccggccgttccggccgttccggccgttccggccgttccggccgt
 gatgtctcagctgtatcgaaaagccgttgcggccgttccggccgttccggccgttccggccgttccggccgt
 tggccgttccggccgttgcggccgttccggccgttccggccgttccggccgttccggccgttccggccgtt
 30
 cggccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 tcccgtaatgacaacagacttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 agaaagttagtccagcatggcagagatgaagaccgttccggccgttccggccgttccggccgttccggccgt
 atctccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 35
 gccggccggacggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgtt
 gagatctcgacgaaatattcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgat
 tcgcaatgggttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 40
 cgggtatcgaggccgcggcaagcgcaatccaggaaatgtcacgtccatttcggccgttccggccgttccggccgt
 agtccctgaccaagctcgacgcggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 acgcccacggctaccgagctgaacaacgcgtcgacgaaacctggccggacgatcagcgttccggccgttccggccgt
 45
 cttcgaccgaaggcaacgtcactggatgtcgataggcaacgcggagttcgcttccggccgttccggccgttccggccgt
 atcgggcgagttcgacccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 catggccggccactacgacaagcttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 gtttcgaccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 50
 gccccccacgtccgacgacctgtcgacgcggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 tccgccaactccgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgat
 cccatgcccattccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 accggcccccacccaaaccaccacaccatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgat
 ggcgcggcccccacccaaaccaccacaccatcgatcgatcgatcgatcgatcgatcgatcgatcgat
 accctcgacggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 cccgcccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 tgcgcgcgggggttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 ggcgcggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 ccaaccgagatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgatcgat
 caactccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 aattacggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 aaggccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 ggtgtcgacgcgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 gtacgagctggacccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgttccggccgt
 aggtggggctggcaaaaccacgctgacagcagcgttgggtcgacggttgggtcgaggttgggtcgaggttgggtcg
 ggctctaga

55

PE coding sequence (SEQ ID No 2)

5 atggaaaaaaatgtcacatgatccgatcgctgccgacattggcacgcaagtgagcgacaacgctctgcacggcgt
acggccggctcgacggcgctgacgtcggtgaccggctggttcccgccccggccatgaggtctccgcccagcg
gcgacggcgttcacatcgagggatccaattgctggcttccaatgcacgcggcccaagaccagctccaccgtcg
ggcqaqcqgtccaggacgtcgccccgacctattcgcaaatcgacgacggcgccggcgtttcgccgaa

10 BPF coding sequence (SEQ ID No. 3)

atgctgtggcacgcaatgccaccggagctaaataccgcacggctgatggccggcgccccgtccggctccaaatgctt
15
gcggcggccgcggatggcagacgcgtttcggcggctctggacgcgtcaggccgtcgagttgaccgcgcgcctgaactct
tctctggagaagcctggactggaggtggcagcacaaggcgctgcggctgcaacgcccgtgggtctggcta
caaaccgcgtcaacacacaggccaagagaccgtgcgtatgcaggcgacggcgcaagccgcggcataacaccaggccatg
gccacgacgcccgtcgctgccggagatcgccgccaaccacatcaccaggccgtcctacggccaccaacttcttc
ggtatcaacacgatcccgatcgcggtgaccgagatggattattcatccgtatgtggaaaccaggcagccctggca
atggaggtctaccaggccgagaccgcggtaaacacgcgtttcgagaagctcgagccgtggcgatcgatccttgc
20
cccgccgcgagccagagcacgacgaaaccgttcggaatgccctccctggcagctcaacaccggttggccag
ttgccgcggcggctaccaggccaaactgggtgagatgagccgcgtgcagcagctgacccaggcc
ctgcagcaggtgacgtcggtttcagccagggtggccggcaccggcgccgcaaccaggccgtcgacgaggaaaggcccg
cagatgggcctgctcgccaccagtccgcgtcgtaaccatccgcgtggctggatcaggccccagcgccggcg
ggcctgctgcgcgcggagtcgctacctggcgcaagggtggtcgttgcaccgcacgcgtgatgtctcagctgatc
gaaaagccgggtgccccctcggtgatgccggcggtgcgtggatcgccggatcgccgcacgggtggccgc
25
ggcggagcgatggccagggtgcgcaatccggcggtccaccaggccgggtctggtcgcgcggcaccgc
gcacaaaggaaqcgtaaaqaaqaaqaaqactqqqacqaaqaaqgacgactgg

CFP-10 coding sequence (SEQ ID No 4)

30 atggcagagatgaagaccgatgccgctaccctcgcgaggaggcaggttaattcgagcggatctccggcgacctg
aaaaccagatcgaccaggtggagtcgacggcaggttcggtgcagggccagtggcgccggcggggacggcc
gcccaaggccgcgggtggtgcgcttccaagaagcagccaataagcagaactcgacgagatctcgacgaat
attcgatcaaggccaaatcgatccaataactcgaaaggccqacqaaqcaqcaqgcqctgtcctcgcaaatgggcttc

ESAT-6 coding sequence (SEO ID No 5)

40 Atgacagagcagcagtggatttcgcggtatcgaggccggcaagcgcaatccaggaaatgtcacgtccatt
catccctccttgcgcgggaaagcagtcgcgcggctggggcggtgcgttcggaggcg
taccagggtgtccagcaaaaatggacgccacggctaccgagctgaacaacgcgcgtgcagaacctggcgccgacg
atcaqcgaaqccqgtcaggcaatqqcttcgaccgaaggcaacgtcactggatgtcgca

CFP-10 + ESAT-6 (SEQ ID NO 6)

45 atggcagagatgaagaccgatgccgctaccctcgcgaggaggcaggtaattcgagcgat
ctccggcgacctgaaaacccagatcgaccagggtggagtcacggcaggttcggtcaggcc
agtggcgccggcgccggggacggcccccaggccgcggtg
50 gtgcgcgttccaagaaggcagccaataaggcagaaggcaggactcgacgagatctcgacgaatat
tcgtcaggccggcggtccaaatactcgagggccgacgaggagcagcagcaggcgctgtcctcg
aaatgggcttctgaccggcttaatacgaaaagaaacggagcaaaaacatgacagagcagcagt
ggaatttcgcgggtatcgaggccggcaagcgcaatccaggaaatgtcacgtccattcat
tccctccttqacqagggaaaagcaqtcctqaccaagctcgcagcggcctggggcggtagcg

5
ttcggaggcgtaaccagggtgtccagaaaaatgggacgccacggctaccgagctgaacaacg
cgctcgagaacctggcgccggacatcagcgaagccggtcaggcaatggctcgaccgaaggc
aacgtcactggatgttcgca

Primer SP6-BAC1
AGTTAGCTCACTCATTAGGCA (SEQ ID No 7)

10
Primer T7-BAC1
GGATGTGCTGCAAGGCGATTA (SEQ ID No 8)

15
primer esat-6F
GTCACGTCCATTCAATTCCCT (SEQ ID No 9);

20
primer esat-6R
ATCCCAGTGACGTTGCCTT) (SEQ ID No 10),

25
primer RD1^{mic} flanking region F
GCAGTGCAAAGGTGCAGATA (SEQ ID No 11);

30
primer RD1^{mic} flanking region R
GATTGAGACACTTGCCACGA (SEQ ID No 12)

35
primer plcA.int.F
CAAGTTGGGTCTGGTCGAAT (SEQ ID No 13)

40
primer plcA.int.R
GCTACCCAAGGTCTCCTGGT (SEQ ID No 14))

Sequences at the junction RD1^{mic}
45
CAAGACGACGGTTGTAACACCTCGACGCAGGATGGCGATGAAATGCCAGTCGGCGTCGCTGAGCGCGCGCTGCC
CGAGTCCCATTTGTCGCTGATTGTTAACAGCGACGAACCGGTGTTGAAAATGTCGCCCTGGGTGGGGATT
CCT (SEQ ID No 15)

50
primer RD5^{mic} flanking region F
GAATGCCGACGTCAATATCG (SEQ ID No 16)

55
primer RD5^{mic} flanking region R
CGGCCACTGAGTTGATTAT (SEQ ID No 17)

Sequence at the junction RD5^{mic}
55
CCTCGATGAACCACCTGACATGACCCCATCCTTCAAGAACTGGAGTCTCCGGACATGCCGGGGCGGTTCACTG
CCCCASGTGTCCTGGTCGTTGACCGTCGAGTCCGAACATCCGTATTCCCGGTGGCAGTCGGTGCGGTG
AC (SEQ ID No 18)

primer MiD1 flanking region F
55
CAGCCAACACCAAGTAGACG (SEQ ID No 19)

5 primer Mid1 flanking region R
TCTACCTGCAGTCGCTTGTG (SEQ ID No 20)

10 Sequence at the junction Mid1
CACCTGACATGACCCCATCCTTCCAAGAACTGGAGTCTCCGGACATGCCGGGCGGTTCAGGGACTTCCATGTC
CATCTTCTGGCAGATCAGCAGATCGCTTCTCAGTGCAGGTGAGTC (SEQ ID No 21)

15 primer Mid2 flanking region R
GTCCATCGAGGATGTCGAGT (SEQ ID No 22)

20 primer Mid2 flanking region L
CTAGGCCATTCCGTTGTCTG (SEQ ID No 23)

25 Sequence at the junction Mid2
GCTGCCTACTACGCTCAACGCCAGAGACCAGCCGCCGGCTGAGGTCTCAGATCAGAGAGTCTCCGGACTCACCGG
GGCGGTTCAAAAGGCTTCGAGACCGGACGGGCTGTAGGTTCTCAACTGTGTGGCGGATGGTCTGAGCACTTAA
C (SEQ ID No 24)

30 primer Mid3 flanking region R
GGCGACGCCATTcc (SEQ ID No 25)

35 primer Mid3 flanking region L
AACTGTGGGCTTGCTCTT (SEQ ID No 26)

40 Sequence at the junction Mid3
TGGCGCCGGCACCTCCGTTGCCACCGTTGCCGCCGCTGGTGGGCCGGTGCCGTTGCCCGGGCGAACCGTTCA
GGGCCGGGTTCGCCCTCAGCCGCTAACACGCCGACCAAGATCAACGAGCTACCTGCCCGGTCAAGGTTGAAGAG
CCCCCATATCAGCAAGGGCCCGGTGTCGGCG (SEQ ID No 27)

45

50

55

SEQUENCE LISTING

<110> INSTITUT PASTEUR

5 <120> Identification of virulence associated regions RD1 and
RD5 leading to improve vaccine of *M. bovis* BCG and *M.*
microti

10 <130> D20217

<140> EP 02/290864
<141> 2002-04-05

<160> 27

15 <170> PatentIn Ver. 2.1

<210> 1
<211> 3909
<212> DNA

20 <213> *Mycobacterium tuberculosis*

<220>

<223> RD1-AP34 (a 3909 bp fragment of the *M.*
tuberculosis H37Rv genome)

25 <400> 1

gaattcccat ccagttagtt caaggtcaag cggcgccccc ctggccaggc atttctcgtc 60
tcgcccagacg gcaaagaggt catccaggcc ccctacatcg agcctccaga agaagtgttc 120
gcagcacccc caagcgccgg ttaagattat ttcattgccc gtgttagcagg acccgagctc 180
agcccggtaa tcgagttcgg gcaatgtga ccatcggtt tgtttccggc tataaccgaa 240
cggtttgtgt acgggataca aatacaggga gggagaagaatgg aggcaaatgg aaaaaatgtc 300
acatgatccg atcgctgccg acattggcac gcaagtgagc gacaacgctc tgcacggcgt 360
gacggccggc tgcacggcgc tgacgtcggt gaccgggctg ttcccgcgg gggccgatga 420
ggtctccgcc caagcggcga cggcggtcac atcgaggggc atccaaattgc tggcttccaa 480
tgcacatggcc caagaccagc tccacccgtgc gggcgaagcg gtccaggacg tcgcccgcac 540
ctattcgcaa atcgacgacg ggcggccggc cgtcttcgcc gaataggccc ccaacacatc 600
ggagggagtg atcaccatgc, tgtggcacgc aatgccacccg gagctaaata cccgacggct 660
gatggccggc gcggttccgg ctccaaatgct tgccggccgc gcggtatggc agacgctttc 720
ggcggctctg gacgctcagg cctgtcgagtt gaccgcgcgc ctgaactctc tgggagaagc 780
ctggacttgg agtggcagcg acaaggcgct tgccgtcgca acgcccgttgg tggctctggct 840
acaaaccgcg tcaacacagg ccaagacccg tgccgtcgac ggcacggcgc aagccgcggc 900
atacacccag gccatggcca cgacggcgtc gctgccggag atcgccgcca accacatcac 960
ccaggccgtc cttacggcca ccaacttctt cggtatcaac acgatcccgaa tcgcgttgac 1020
cgagatggat tatttcatcc gtatgtggaa ccaggcagcc ctggcaatgg aggtctacca 1080
ggccgagacc gcggttaaca cgctttcga gaagctcgag ccgtatggcgt cgatccttga 1140
tcccggcgcg agccagagca cgacgaaccc gatcttcgga atgccttccc ctggcagctc 1200
aacacccgtt gcccgttgc cgccggccgc taccctcgacc ctgcggccaa tgggtgagat 1260
gagcggcccg atgcagcagc tgacccagcc gctgcagcag gtgacgtcgat ttgcagcca 1320
ggtggccggc acggcgccgc gcaacccaggc cgacgaggaa gcccgcaga tgggcctgct 1380
cgccaccagt cgcgtgtcga accatccgtt ggctgggtgg tcaggccccca ggcggggcgc 1440
gggcctgctg cgcgcggagt cgctacctgg cgcagggtgg tcgttgaccc gcaacggcgct 1500
gtatgtctcag ctgatcgaaa agccgggtgc cccctcggtt atgcggccgg ctgtcgccgg 1560
atcgtcggcg acgggtggcg cgcgtccgtt gggtgccgg ggcgtgggccc aggggtgcgc 1620
atccggccggc tccaccaggc cgggtctggc cgcgcggca cgcgtcgccg aggagcgtga 1680
agaagacgac gaggacgact gggacgaaga gacgactgg tgacgtcccg taatgacaac 1740
agacttcccg gccacccggg cccggaaagact tgccaaacatt ttggcgagga aggtaaagag 1800
agaaaagtgt ccagcatggc agagatgaag accgatgccg ctaccctcgc gcaggaggca 1860
gttaatttcg agcggatctc cggcgacctg aaaacccaga tcgaccaggt ggagtcgacg 1920
gcaggttcgt tgcagggcca gtggcgccgc gcccggggga cggccgcaca ggccgcgggt 1980
gtgcgttcc aagaagcagc caataagcag aacgacgat ctcgacgaaat 2040

attcgtcagg ccggcgtcca atactcgagg gccgacgagg agcagcagca ggcgctgtcc 2100
 tcgcaaatgg gcttctgacc cgctaatacg aaaagaaaacg gagcaaaaac atgacagagc 2160
 5 agcagtggaa tttcgcggt atcgaggccg cggcaagcgc aatccaggga aatgtcacgt 2220
 ccattcattc ctccttgac gaggggaagc agtccctgac caagctcgca gcccctggg 2280
 gcggtagcgg ttcggaggcg taccagggtg tccagcaaaa atgggacgcc acggctaccg 2340
 agctgaacaa cgcgtgcag aacctggcgc ggacgatcag cgaagccggt caggcaatgg 2400
 10 cttcgaccga aggcaacgtc actggatgt tcgcataagg caacgcccgg ttcgcgtaga 2460
 atagcgaaac acgggatcgg gcgagttcga cttccgtcg gtctcgccct ttctcggtt 2520
 tatacgttt agcgactct gagaggtgt catggcgcc gactacgaca agctttccg 2580
 gccgcacgaa ggtatgaaag ctccggacga tatggcagcg cagccgttct tcgaccccaag 2640
 15 tgcttcgtt ccggcgccgc cgcatecgcc aaacctaccg aagcccaacg gccagactcc 2700
 gcccccgacg tccgacgacc tgcggagcg gttcgtgtcg gccccggccgc cggccaccc 2760
 accccccaccc cggcctccgc caactccgat gccgatcgcc gcaggagagc cggccctcgcc 2820
 ggaaccggcc gcatctaaac caccacacc ccccatgccc atgcgggac cgaaccggc 2880
 20 cccacccaaa ccacccacac ccccatgccc catgcggga cccgaaccgg cccacccaa 2940
 accacccaca cctccgatgc ccatgcggg acctgcaccc accccaaaccg aatcccagt 3000
 ggcgcggccc agaccaccga caccacaaac gccaaccgg ggcgcgcagg aaccggaatc 3060
 accggcgcggc cacgtaccct cgcacgggac acatcaaccc cggcgcaccg caccagcacc 3120
 25 gcccctggca aagatgccaat tcggcgaacc cccggccgtt ccttcagac cgtctcggtc 3180
 cccggccgaa ccaccgaccc ggcctggccc ccaacactcc cgacgtgcgc gccgggtca 3240
 cgcgtatcgc acagacaccg aacgaaacgt cgggaaggta gcaactggtc catccatcca 3300
 ggcgcggctg cggcgagg aagcatccgg cgcgcagctc gccccggaa cggagccctc 3360
 30 gccagcgccg ttgggccaac cgagatcgta tctggctccg cccacccggc cggcgccgac 3420
 agaacctccc cccagccct cgcgcagcg caactccgtt cggcgtggcg agcgcacgcgt 3480
 ccaccccgat ttagccgccc aacatgcgc ggcgcaccc gattcaatta cggccgcaac 3540
 cactggcggt cgtcgcgcgca agcgtgcagc gccggatctc gacgcgacac agaaatcctt 3600
 35 aaggccggcg gccaaggggc cgaagggtgaa gaagggtgaaag cccagaaac cgaaggccac 3660
 gaagccgccc aaagtgggtt cgcagcgccg ctggcgacat tgggtgcatt cgttgacgcg 3720
 aatcaacctg ggcctgtcac cgcacgagaa gtacgagctg gacctgcacg ctcgagtccg 3780
 cgcacatccc cgcgggtcgatcagatcgc cgtcgtcggt ctcaaagggtg gggctggcaa 3840
 aaccacgctg acagcagcgt tgggtcgac gttggctcag gtgcggcccg accggatcct 3900
 40 ggctctaga 3909

<210> 2
 <211> 297
 <212> DNA
 35 <213> *Mycobacterium tuberculosis*

<220>
 <223> PE coding sequence

<400> 2
 40 atggaaaaaaa tgcacatga tccgatcgct gccgacattg gcacgcaagt gagcgacaac 60
 gctctgcacg gcgtgacggc cggctcgacg gcgctgacgt cggtgcaccgg gctggttccc 120
 gcgccggccg atgaggtctc cggccaaagcg gcgacggcggt tcacatcgga gggcatccaa 180
 ttgctggctt ccaatgcac ggcacaaagac cagctccacc gtgcgggcga agcggtccag 240
 gacgtcgccc gcacccatttc gcaaatcgac gacggcgcgg cggcgctt cggccaa 297

45 <210> 3
 <211> 1104
 <212> DNA
 50 <213> *Mycobacterium tuberculosis*

<220>
 <223> PPE coding sequence

<400> 3
 55 atgctgtggc acgcaatgcc accggagcta aataccgcac ggctgatggc cggcgccgggt 60
 ccggctccaa tgcttgccgc ggccggggaa tggcagacgc tctggacgct 120

5 caggccgtcg agttgaccgc gcgcctgaac tctctggag aagcctggac tggaggtggc 180
agcgacaagg cgcttgcggc tgcaacgccc atggtgtct ggctacaaac cgctcaaca 240
caggccaaga cccgtgcgt gcaggcgacg ggcgaagccg cggcatacac ccaggccatg 300
gccacgacgc cgtcgctgcc ggagatcgcc gccaaccaca tcacccaggc cgtccttacg 360
gccaccaact tcttcggtat caacacgatc cggatcggt tgaccgagat ggattatttc 420
atccgtatgt ggaaccaggc agccctggca atggaggtct accaggccga gaccgcgg 480
aacacgctt tcgagaagct cgagccgatg gcgtcgatcc ttgatcccgg cgcgagccag 540
agcacgacga acccgatctt cggaatgccc tcccctggca gctcaacacc ggttggccag 600
ttgcccggcgg cggctaccca gaccctcgcc caactgggtg agatgagcgg cccgatgcag 660
cagctgaccc agccgctgca gcaggtgacg tcgttgcgtca gccaggtggg cggcaccggc 720
ggcggcaacc cagccgacga ggaagcccg cagatgggcc tgctcgac cagtcggctg 780
tcgaaccatc cgctggctgg tggatccaggc cccagcgcgg gcgcgggcct gctgcgcgc 840
gagtcgctac ctggcgccagg tgggtcggtg acccgacgc cgctgatgtc tcagctgatc 900
gaaaagccgg ttgccccctc ggtgatgccg gcggctgctg ccggatcgac ggcgacgggt 960
ggcgccgctc cggtggtgc gggagcgatg ggccagggtg cgcaatccgg cggctccacc 1020
aggccgggtc tggtcgccc ggcaccgctc gcgcaggagc gtgaagaaga cgacgaggac 1080
gactgggacg aagaggacga ctgg 1104

20 <210> 4
<211> 300
<212> DNA
<213> *Mycobacterium tuberculosis*

25 <220>
<223> CFP-10 coding sequence

30 <400> 4
atggcagaga tgaagaccga tgccgctacc ctcgcgcagg aggcaggtaa tttcgagcgg 60
atctccggcg acctgaaaac ccagatcgac caggtggagt cgacggcagg ttctgtgcag 120
ggccagtggc gcggcgccggc gggacggcc gcccaggccg cggtggtgcg cttccaagaa 180
gcagccaata agcagaagca ggaactcgac gagatctcgat cgaatattcg tcaggccggc 240
gtccaaatact cgaggccga cgaggagcag cagcaggcgc tgcctcgca aatgggcttc 300

35 <210> 5
<211> 285
<212> DNA
<213> *Mycobacterium tuberculosis*

40 <220>
<223> ESAT-6 coding sequence

45 <400> 5
atgacagagc agcagtggaa tttcgccggat atcgaggccg cggcaagcgc aatccaggaa 60
aatgtcacgt ccattcattc cctccttgcac gaggagaagc agtccctgac caagctcgca 120
gcggcctggg gcggtagcgg ttcggaggcg taccagggtg tccagcaaaa atgggacgccc 180
acggctaccg agctgaacaa cgcgcgtgcag aacctggcgc ggacgatcag cgaagccgg 240
caggcaatgg cttcgaccga aggcaacgtc actggatgt tcgca 285

50 <210> 6
<211> 620
<212> DNA
<213> *Mycobacterium tuberculosis*

55 <220>
<223> CFP-10 + ESAT-6

<400> 6
atggcagaga tgaagaccga tgccgctacc ctcgcgcagg aggcaggtaa tttcgagcgg 60

atctccggcg acctgaaaac ccagatcgac caggtggagt cgacggcagg ttcgttgcag 120
 ggccagttgc gcggcgccggc ggggacggcc gcccaggccg cgtgggtgcg cttccaagaa 180
 5 gcagccaata agcagaagca ggaactcgac gagatctcg a cgaatattcg tcaggccggc 240
 gtccaaatct cgagggccga cgaggagcag cagcaggccg tgcctcgca aatgggcttc 300
 tgacccgcta atacgaaaag aaacggagca aaaacatgac agagcagcag tggaaattcg 360
 cgggtatcga ggccgcggca agcgcaatcc agggaaatgt cacgtccatt cattccctcc 420
 ttgacgaggg gaagcagtcc ctgaccaagc tcgcagccgc ctggggccgt agcggttcgg 480
 aggcgtacca gggtgtccag caaaaatggg acgcccacggc taccgagctg aacaacgcgc 540
 10 tgcagaacct ggccgcggacg atcagcgaag ccggtcaggc aatggcttcg accgaaggca 600
 acgtcactgg gatgttcgca 620

<210> 7
 <211> 21
 15 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer
 SP6-BAC1

20 <400> 7
 agttagctca ctcatttaggc a 21

<210> 8
 25 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer T7-BAC1

30 <400> 8
 ggatgtgctg caaggcgatt a 21

<210> 9
 35 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 40 <223> Description of Artificial Sequence: Primer esat-6F

<400> 9
 gtcacgtcca ttcatccct 20

45 <210> 10
 <211> 19
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Description of Artificial Sequence: Primer esat-6R

<400> 10
 atcccagtga cgttgcctt 19

55

5 <210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence: Primer RD1^{mic}
flanking region F

15 <400> 11
gcagtgcaaa ggtgcagata

20 <210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence: Primer RD1^{mic}
flanking region R

30 <400> 12
gattgagaca cttgccacga

35 <210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: Primer
plcA.int.F

45 <400> 13
caagttgggt ctggtcgaat

50 <210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

55 <220>
<223> Description of Artificial Sequence: Primer
plcA.int.R

60 <400> 14
gctacccaag gtctcctgg

65 <210> 15
<211> 153
<212> DNA
<213> Mycobacterium tuberculosis

70 <220>
<223> Sequences at the junction RD1^{mic}

75 <400> 15

5 caagacgagg ttgtaaaaacc tcgacgcagg atcggcgatg aaatgccagt cggcgctcgct 60
 gagcgccgcg cgcgcccggact cccatggatcgctgatttgc tttgaacagc gacgaaccgg 120
 tgttgaaaat gtcgcctggg tcggggattc cct 153

10 <210> 16
 <211> 19
 <212> DNA
 <213> Artificial Sequence

15 <220>
 <223> Description of Artificial Sequence: Primer RD5^{mic}
 flanking region F

20 <400> 16
 gaatgccgac gtcatatacg 19

25 <210> 17
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Primer RD5^{mic}
 flanking region R

30 <400> 17
 cggccactga gttcgattat 20

35 <210> 18
 <211> 152
 <212> DNA
 <213> Mycobacterium tuberculosis

40 <220>
 <223> Sequence at the junction RD5^{mic}

<400> 18
 cctcgatgaa ccacccatc tgaccccatc cttccaaga actggagtc cggacatgc 60
 cggggcggtt cactgccccca ggtgtccctgg gtcgttccgt tgaccgtcga gtccgaacat 120
 ccgtcattcc cggtggcagt cggtgcggtg ac 152

45 <210> 19
 <211> 20
 <212> DNA
 <213> Artificial Sequence

50 <220>
 <223> Description of Artificial Sequence: Primer MiD1
 flanking region F

55 <400> 19
 cagccaaacac caagtagacg 20

<210> 20
 <211> 20
 <212> DNA

```

<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence: Primer MiD1
      flanking region R

<400> 20
tctacacctgca gtcgcttgtg 20
10

<210> 21
<211> 123
<212> DNA
<213> Mycobacterium tuberculosis
15 <220>
<223> Sequence at the junction MiD1

<400> 21
cacctgacat gaccccatcc tttccaagaa ctggagtctc cggacatgcc ggggcggg 60
20 agggacatcc atgtccatct tctggcagat cagcagatcg cttgttctca gtgcagg 120
gtc 123

<210> 22
25 <211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer MiD2
30      flanking region R

<400> 22
gtccatcgag gatgtcgagt 20
35

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence: Primer MiD2
      flanking region L

<400> 23
ctaggccatt ccgttgtctg 20
45

<210> 24
<211> 151
<212> DNA
<213> Mycobacterium tuberculosis
50 <220>
<223> Sequence at the junction MiD2

<400> 24
55 gctgcctact acgctcaacg ccagagacca gccggcggt gaggtctcag atcagagagt 60
ctccggactc accggggcgg ttcataaagg cttcgagacc ggacgggctg taggttctc 120

```

aactgtgtgg cgatggtct gagcaactaa c 151
 5
 <210> 25
 <211> 15
 <212> DNA
 <213> Artificial Sequence
 10
 <220>
 <223> Description of Artificial Sequence: Primer MiD3
 flanking region R
 <400> 25
 15
 ggcgacgcca tttcc 15
 <210> 26
 <211> 19
 <212> DNA
 20
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Primer MiD3
 flanking region L
 25
 <400> 26
 aactgtcggg cttgctctt 19
 <210> 27
 30
 <211> 181
 <212> DNA
 <213> *Mycobacterium tuberculosis*
 <220>
 <223> Sequence at the junction MiD3
 35
 <400> 27
 tggcgccggc acctccgttg ccaccgttgc cgccgctggc gggcgccggc cggccgccc 60
 cggccgaacc gttcaggccc gggttcgccc tcagccgcta aacacgccc ccaagatcaa 120
 cgagctacct gcccggtcaa ggttgaagag ccccccataatc agcaaggccc cgggtgtccgc 180
 g 181
 40

42. **van Embden, J. D., T. van Gorkom, K. Kremer, R. Jansen, B. A. van Der Zeijst, and L. M. Schouls.** 2000. Genetic variation and evolutionary origin of the direct repeat locus of *Mycobacterium tuberculosis* complex bacteria. *J. Bacteriol.* **182**:2393-2401.
 43. **van Soolingen, D., A. G. M. Van Der Zanden, P. E. W. De Haas, G. T. Noordhoek, A. Kiers, N. A. Foudraine, F. Portaels, A. H. J. Kolk, K. Kremer, and J. D. A. Van Embden.** 1998. Diagnosis of *Mycobacterium microti* infections among humans by using novel genetic markers. *J. Clin. Microbiol.* **36**:1840-1845.
 44. **Vera-Cabrera, L., M. A. Hernandez-Vera, O. Welsh, W. M. Johnson, and J. Castro-Garza.** 2001. Phospholipase region of *Mycobacterium tuberculosis* is a preferential locus for IS6110 transposition. *J. Clin. Microbiol.* **39**:3499-3504.
 45. **Wells, A. Q.** 1937. Tuberculosis in wild voles. *Lancet* 1221.
 46. **Wells, A. Q.** 1946. The murine type of tubercle bacillus. *Medical Research council special report series* **259**:1-42.
 47. **Wheeler, P. R., and C. Ratledge.** 1992. Control and location of acyl-hydrolysing phospholipase activity in pathogenic mycobacteria. *J. Gen. Microbiol.* **138**:825-830.

Claims

1. A strain of *M. bovis* BCG or *M. microti*, wherein said strain has integrated all or part of the RD1 region responsible for enhanced immunogenicity and increased persistence of BCG to the tubercle bacilli.

5 2. A strain according to claim 1 which has integrated a portion of DNA originating from *Mycobacterium tuberculosis*, which comprises at least one gene selected from Rv3872 (SEQ ID No 2, mycobacterial PE), Rv3873 (SEQ ID No 3, PPE), Rv3874 (SEQ ID No 4, CFP-10), and Rv3875 (SEQ ID No 5, ESAT-6).

10 3. A strain according to claim 1 which has integrated a portion of DNA originating from *Mycobacterium tuberculosis*, which comprises Rv3875 (SEQ ID No 5, ESAT-6).

4. A strain according to claim 1 which has integrated a portion of DNA originating from *Mycobacterium tuberculosis*, which comprises Rv3874 (SEQ ID No 4, CFP-10).

15 5. A strain according to claim 1 which has integrated a portion of DNA originating from *Mycobacterium tuberculosis*, which comprises both Rv3875 (SEQ ID No 5, ESAT-6) and (SEQ ID No 4, CFP-10).

20 6. A strain according to one of claims 2 to 5, wherein the coding sequence of the integrated gene is in frame with its natural promoter or with an exogenous promoter, such as a promoter capable of directing high level of expression of said coding sequence.

7. A strain according to one of claims 1 to 5, wherein said the integrated gene is mutated so as to maintain the improved immunogenicity while decreasing the virulence of the strain.

25 8. A strain according to claim 7, wherein said strain only carries parts of the genes coding for ESAT-6 or CFP-10 in a mycobacterial expression vector under the control of a promoter, more particularly an hsp60 promoter.

9. A strain according to claim 8, wherein said strain carries at least one portion of the esat-6 gene that codes for immunogenic 20-mer peptides of ESAT-6 active as T-cell epitopes.

10. A strain according to claim 7, wherein the esat-6 and CFP-10 encoding genes are altered by directed mutagenesis in a way that most of the immunogenic peptides of ESAT-6 remain intact, but the biological functionality of ESAT-6 is lost.

35 11. *M. bovis* BCG::RD1 strains which have integrated a cosmid herein referred as RD1-2F9 and RD1-AP34 contained in the *E. coli* strains deposited at the CNCM under the accession number I-2831 and I-2832 respectively.

40 12. *M. bovis* BCG::RD1 strain which has integrated the construct RD1-AP34 which contains a 3909 bp fragment of the *M. tuberculosis* H37Rv genome from region 4350459 bp to 4354367 bp cloned (SEQ ID No 1).

13. *M. bovis* BCG::RD1 strain which has integrated the fragment RD1-2F9 (~ 32 kb) that covers the region of the *M. tuberculosis* genome AL123456 from ca 4337 kb to ca. 4369 kb.

45 14. *M. microti*::RD1 strain which has integrated the construct RD1-AP34 which contains a 3909 bp fragment of the *M. tuberculosis* H37Rv genome from region 4350459 bp to 4354367 bp cloned (SEQ ID No 1).

15. *M. microti*::RD1 strain which has integrated the fragment RD1-2F9 (~ 32 kb) that covers the region of the *M. tuberculosis* genome AL123456 from ca 4337 kb to ca. 4369 kb.

50 16. A method for preparing and selecting improved *M. bovis* BCG or *M. microti* strains defined in one of claims 1 to 15 comprising a step consisting of modifying said strains by insertion, deletion or mutation in the integrated DR1 region, more particularly in the esat-6 or CFP-10 gene, said method leading to strains that are less virulent for immuno-depressed individuals.

55 17. A cosmid or a plasmid comprising all or part of the RD1 region originating from *Mycobacterium tuberculosis*, said region comprising at least one gene selected from Rv3872 (mycobacterial PE), Rv3873 (PPE), Rv3874 (CFP-10), and Rv3875 (ESAT-6).

18. A cosmid or a plasmid according to claim 17 comprising CFP-10, ESAT-6 or both or a part of them.

19. A cosmid or a plasmid according to claim 18 comprising a mutated gene selected CFP-10, ESAT-6 or both., said mutated gene being responsible for the improved immunogenicity and decreased virulence.

5 20. Use of a cosmid or a plasmid according to one of claims 17 to 19 for transforming *M. bovis* BCG or *M. microti*.

10 21. A pharmaceutical composition comprising a strain according to one of claims 1 to 15 and a pharmaceutically acceptable carrier.

22. A pharmaceutical composition according to claim 21 containing suitable pharmaceutically-acceptable carriers comprising excipients and auxiliaries which facilitate processing of the living vaccine into preparations which can be used pharmaceutically.

15 23. A pharmaceutical composition according to claim 21 or 22 which is suitable for intravenous or subcutaneous administration.

24. A vaccine comprising a strain according to one of claims 1 to 15 and a suitable carrier.

20 25. A product comprising a strain according to one of claims 1 to 15 and at least one protein selected from ESAT-6 and CFP-10 or epitope derived thereof for a separate, simultaneous or sequential use for treating tuberculosis.

26. The use of a strain according to one of claims 1 to 15 for preparing a medicament or a vaccine for preventing or treating tuberculosis.

25 27. The use of a strain according to one of claims 1 to 15 as an adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

28. A method for the identification at the species level of members of the *M. tuberculosis* complex by means of markers for RD1^{mic} and RD5^{mic} as molecular diagnostic test.

30 29. A method according to claim 28 comprising the use of a primer selected from :

35 primer esat-6F GTCACGTCCATTCAATTCCCT (SEQ ID No 9),

40 primer esat-6R ATCCCAGTGACGTTGCCTT) (SEQ ID No 10),

45 primer RD1^{mic} flanking region F GCAGTGCAAAGGTGCAGATA (SEQ ID No 11),

50 primer RD1^{mic} flanking region R GATTGAGACACTGCCACGA (SEQ ID No 12),

55 primer RD5^{mic} flanking region F GAATGCCGACGTCATATCG (SEQ ID No 16),

primer RD5^{mic} flanking region R CGGCCACTGAGTTGATTAT (SEQ ID No 17)

and the complementary sequences of said primers.

55 30. A diagnostic kit for the identification at the species level of members of the *M. tuberculosis* comprising DNA probes and primers specifically hybridizing to a DNA portion of the RD1 or RD5 region of *M. tuberculosis*, more particularly probes hybridizing under stringent conditions to a gene selected from Rv3871, Rv3872 (mycobacterial PE), Rv3873

(PPE), Rv3874 (CFP-10), Rv3875 (ESAT-6), and Rv3876, preferably CFP-10 and ESAT-6.

31. A diagnostic kit according to claim 30 comprising a probe or primer selected from :

5 esat-6F GTCACGTCCA^TTCATTCCCT (SEQ ID No 9),

10 esat-6R ATCCCAGTGACGTTGCCTT) (SEQ ID No 10),

15 RD1^{mic} flanking region F GCAGTGCAAAGGTGCAGATA (SEQ ID No 11),

RD1^{mic} flanking region R GATTGAGACACTGCCACGA (SEQ ID No 12),

20 RD5^{mic} flanking region F GAATGCCGACGTCATATCG (SEQ ID No 16),

RD5^{mic} flanking region R CGGCCACTGAGTTCGATTAT (SEQ ID No 17).

32. A diagnostic kit for the identification at the species level of members of the *M. tuberculosis* comprising antibodies
25 directed to mycobacterial PE, PPE, CFP-10 and ESAT-6.

33. Virulence markers associated with RD1 and/or RD5 regions of the genome of *M. tuberculosis* or a part of these
regions.

30

35

40

45

50

55

RD1 DELETION M. microti




FIGURE 1A

4,340,417

ANDI DEI ETI

RD1 DELETION BCG

ESAV-6 family conserved blocks region

Deleted Region		Coordinates (kilobase)	Putative virulence genes and their function	Integrating clones
RD3	1779-1788		Prophage phiRv1 (Rv1573-1586)	RD3-1301
RD4	1696-1708		Extracellular polysaccharide synthesis (Rv1511-Rv1514)	RD4-1375
RD5	2626-2635		Phospholipase operon (plicA, plicB, plicC)	RD5-1B1
RD7	2208-2220		Adhesin/invasin (mico3 operon)	RD7-1B9
RD9	2330-2332		Cobalamin synthesis (cbl)	RD9-1493

FIGURE 1B




FIGURE 1C



FIGURE 1D

FIGURE 2A




FIGURE 2B



FIGURE 2C




FIGURE 2D




FIGURE 3A




FIGURE 3B




FIGURE 3C




FIGURE 3D








FIGURE 4A**FIGURE 4B****FIGURE 4C****FIGURE 4D**

EP 1 350 839 A1




FIGURE 5




FIGURE 7A




FIGURE 7B

FIGURE 8A




FIGURE 8B



FIGURE 8C




FIGURE 8D






FIGURE 9



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 02 29 0864
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X, D	<p>MAHAIRAS G G ET AL: "Molecular analysis of genetic differences between <i>Mycobacterium bovis</i> BCG and virulent <i>M. bovis</i>." <i>JOURNAL OF BACTERIOLOGY</i>. UNITED STATES MAR 1996, vol. 178, no. 5, March 1996 (1996-03), pages 1274-1282, XP000647583 ISSN: 0021-9193</p> <ul style="list-style-type: none"> * abstract * * page 1278, right-hand column, paragraph 4 - page 1280, right-hand column, paragraph 2 * * page 1281, right-hand column, paragraph 2 - page 1282, left-hand column, paragraph 1 * * table 3 * <p>-& DATABASE NCBI [Online] NCBI; 27 April 1996 (1996-04-27) MAHAIRAS G. ET AL.: "Mycobacterium bovis deleted region 1, 6 kDa early secretory antigenic target (esat6) gene, complete cds" XP002209499</p> <p>* the whole document *</p>	1-6,11, 13,17, 18,20-26	C12N1/36 A61K39/04 G01N33/569 C12N15/11 C07K14/35
Y		1-6,11, 13,17, 18,20	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12N
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely:</p> <p>Claims searched incompletely:</p> <p>Claims not searched:</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search	Date of completion of the search	Examiner	
MUNICH	3 September 2002	Weiland, S	
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			



Claim(s) searched completely:
1-6, 11-13 and 20-27

Claim(s) not searched:
7-10, 16 and 19

Reason for the limitation of the search:

Present claims 7-10, 16 and 19 relate to a product and method, resp., defined by reference to a desirable characteristic or property, namely to a strain of *M. bovis* BCG with improved immunogenicity and decreased virulence. Though it is specified that this result is to be achieved by mutations of the integrated sequences said mutations are not characterized by technical features but only by the desirable effect on the phenotype of the host strain.

The claims cover all products and methods having this characteristic or property, whereas the application provides no support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for mutations by which the desired result could be achieved and it is to be expected that only a limited number of mutations in certain genes leads to a phenotype that renders the bacteria suitable as vaccine candidates. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the product and method, resp., by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search of the claimed scope impossible.



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 02 29 0864

DOCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim
X	---	
X	WO 99 04005 A (STATENS SERUMINSTITUT ;ANDERSEN PETER (DK); RASMUSSEN PETER BIRK () 28 January 1999 (1999-01-28) * page 1, paragraph 2 * * page 5, paragraph 7 - page 6, paragraph 1 * * page 17, paragraph 2 * * page 44, paragraph 6 - page 46, paragraph 4 * * claims 12,48-53 * -& DATABASE EMBL [Online] EBI; 7 June 1999 (1999-06-07) ANDERSEN P ET AL.: "Regulatory polynucleotide containing M. tuberculosis 1hp/orf1c operons" XP002209498 * the whole document *	1-6,11, 13,17, 18,20-26 27
Y	---	1-6,11, 13,17, 18,20-26
		TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 03.82 (P04C10)



DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	<p>BERTHET F X ET AL: "A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP-10)." MICROBIOLOGY (READING, ENGLAND) ENGLAND NOV 1998, vol. 144 (Pt 11), November 1998 (1998-11), pages 3195-3203, XP002901305 ISSN: 1350-0872</p> <p>* abstract *</p> <p>* page 3198, right-hand column, paragraph 3 - page 3199, left-hand column, paragraph 1 *</p> <p>* page 3202, right-hand column, paragraph 2 *</p> <p>-& DATABASE EMBL [Online] EBI; 29 June 1998 (1998-06-29)</p> <p>BERTHET F. ET AL.: "Mycobacterium tuberculosis H37Rv esat6 promotor region, L45 antigen homologous protein LHP (lhp) gene, complete cdc, and early secreted antigenic target 6 kDa (esat6) gene, partial cds" XP002209500</p> <p>* the whole document *</p> <p>---</p>	1-6,11, 13,17, 18,20	
Y		1-6,11, 13,17, 18,20	TECHNICAL FIELDS SEARCHED (Int.Cl.)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 02 29 0864

DOCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	
Y	<p>WO 99 45119 A (FOLKERSEN JOERGEN ;STATENS SERUMINSTITUT (DK); JENSEN CARSTEN LOEV) 10 September 1999 (1999-09-10)</p> <p>* page 22, paragraph 2 - page 23, paragraph 1 *</p> <p>* page 14, paragraph 2 - page 15, paragraph 3 *</p> <p>* page 17, paragraph 4 - page 18, paragraph 1 *</p> <p>* page 29, paragraph 2 *</p> <p>* page 31, paragraph 2 *</p> <p>* example 3.2 *</p> <p>* claims 47-49 *</p> <p>---</p>	1-6,11, 13,17, 18,20-27
Y	<p>MUSTAFA A S: "Biotechnology in the development of new vaccines and diagnostic reagents against tuberculosis." CURRENT PHARMACEUTICAL BIOTECHNOLOGY. NETHERLANDS JUN 2001, vol. 2. no. 2, June 2001 (2001-06), pages 157-173, XP001098143 ISSN: 1389-2010</p> <p>* abstract *</p> <p>* page 159, left-hand column, paragraph 3 - right-hand column, paragraph 2 *</p> <p>* page 160, left-hand column, paragraph 2 - right-hand column, paragraph 1 *</p> <p>* page 162, right-hand column, paragraph 2</p> <p>- page 165, left-hand column, paragraph 1</p> <p>*</p> <p>---</p> <p>-/-</p>	1-6,11, 13,17, 18,20-27



DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages		
Y	ZHANG YE ET AL: "The signalling pathway for BCG-induced interleukin-6 production in human bladder cancer cells." BIOCHEMICAL PHARMACOLOGY, vol. 63, no. 2, 2002, pages 273-282, XP001098404 15 January, 2002 ISSN: 0006-2952 * page 273, left-hand column, paragraph 1 - right-hand column, paragraph 2 * * abstract * ---	27	
A,D	BROSCH R ET AL: "A new evolutionary scenario for the <i>Mycobacterium tuberculosis</i> complex." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 99, no. 6, 19 March 2002 (2002-03-19), pages 3684-3689, XP002208996 http://www.pnas.org March 19, 2002 ISSN: 0027-8424 * page 3685, right-hand column, paragraph 5 * * page 3688, left-hand column, paragraph 3 * ---	1-6,11, 13,17, 18,20-27	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	BROSCH ROLAND ET AL: "The evolution of mycobacterial pathogenicity: Clues from comparative genomics." TRENDS IN MICROBIOLOGY, vol. 9, no. 9, September 2001 (2001-09), pages 452-458, XP002208997 ISSN: 0966-842X * abstract * * page 455, left-hand column, paragraph 2 - right-hand column, paragraph 2 * * table 1 * -----	1-6,11, 13,17, 18,20-27	



CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):

No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.

As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.

Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:

None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-6, 11, 17, 18, 20-27 (all partial), 13 (complete)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. Claims: 1-6, 11, 17, 18, 20-27 (all partial), 13 (complete)

Recombinant *M. bovis* BCG strain transformed with a construct comprising the entire RD1 region (RD1-2F9), cosmids and plasmids comprising said region and their use for the transformation of *M. bovis* BCG, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

2. Claims: 1, 2, 6, 11-13, 17 and 20-27 (all partial)

Recombinant *M. bovis* BCG strain transformed with a construct comprising part of the RD1 region, i.e. a nucleic acid sequence according to Sequence Id No.2, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. bovis* BCG, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

3. Claims: 1, 2, 6, 11-13, 17 and 20-27 (all partial)

Recombinant *M. bovis* BCG strain transformed with a construct comprising part of the RD1 region, i.e. a nucleic acid sequence according to Sequence Id No.3, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. bovis* BCG, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

4. Claims: 1, 2, 11-13, 17,
18 and 20-27 (all partial) and 4 (complete)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

Recombinant *M. bovis* BCG strain transformed with a construct comprising part of the RD1 region, i.e. a nucleic acid sequence according to Sequence Id No.4, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. bovis* BCG, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

5. Claims: 1, 2, 11-13, 17,
18 and 20-27 (all partial) and 3 (complete)

Recombinant *M. bovis* BCG strain transformed with a construct comprising at least a nucleic acid sequence according to Sequence Id No. 5, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. bovis* BCG, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

6. Claims: 1, 6, 11-13, 17,
18 and 20-27 (all partial) and 5 (complete)

Recombinant *M. bovis* BCG strain transformed with a construct comprising part of the RD1 region, i.e. nucleic acid sequences according to Sequence Id No. 4 and 5, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

7. Claims: 1-6, 11, 17,
18 and 20-27 (all partial) and 12 (complete)

Recombinant *M. bovis* BCG strain transformed with a construct comprising part of the RD1 region (RD1-AP34, Seq Id No. 1),



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

cosmids and plasmids comprising said region and their use for the transformation of *M. bovis* BCG, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

8. Claims: 1-6, 17,
18 and 20-27 (all partial) and 15 (complete)

Recombinant *M. microti* strain transformed with a construct comprising the entire RD1 region (RD1-2F9), cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

9. Claims: 1, 2 , 6, 14, 15, 17 and 20-27 (all partial)

Recombinant *M. microti* strain transformed with a construct comprising part fo the RD1 region, i.e. a nucleic acid sequence according to Sequence Id No. 2, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

10. Claims: 1, 2 , 6, 14, 15, 17 and 20-27 (all partial)

Recombinant *M. microti* strain transformed with a construct comprising a part of RD1, i.e. a nucleic acid sequence according to Sequence Id No. 3, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

11. Claims: 1, 2, 6, 14, 15, 17, 18,
20-27 (all partial) and 4 (complete)

Recombinant *M. microti* strain transformed with a construct comprising a part of RD1, i.e. a nucleic acid sequence according to Sequence Id No. 4, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

12. Claims: 1, 2, 6, 14, 15, 17, 18,
20-27 (all partial) and 3 (complete)

Recombinant *M. microti* strain transformed with a construct comprising a part of RD1, i.e. a nucleic acid sequence according to Sequence Id No. 5, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

13. Claims: 1, 6, 14, 15, 17, 18,
20-27 (all partial) and 5 (complete)

Recombinant *M. microti* strain transformed with a construct comprising a part of RD1, i.e. a nucleic acid sequence according to Sequence Id No. 4 and 5, cosmids and plasmids comprising said nucleic acid sequence and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

14. Claims: 1-6, 17, 18, 20-27 (all partial) and 14 (complete)

Recombinant *M. microti* strain transformed with a construct comprising part of the RD1 region (RD1-AP34, Seq Id No. 1), cosmids and plasmids comprising said region and their use for the transformation of *M. microti*, pharmaceutical compositions and vaccines comprising said strain and use of said strain for preparing a medicament or vaccine for preventing or treating tuberculosis or as adjuvant/immunomodulator for preparing a medicament for the treatment of superficial bladder cancer.

15. Claims: 28-33

Method for the identification at the species level of members of the *M. tuberculosis* complex by means of markers of the RD1 and RD5 region, resp., which are specific for *M. microti*.

ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.

EP 02 29 0864

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.
 The members are as contained in the European Patent Office EDP file on
 The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

03-09-2002

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9904005	A	28-01-1999	AU EP WO US	8123898 A 1003870 A1 9904005 A1 6436409 B1	10-02-1999 31-05-2000 28-01-1999 20-08-2002
WO 9945119	A	10-09-1999	AU AU CA WO EP JP	749672 B2 2611999 A 2322505 A1 9945119 A2 1058731 A2 2002505106 T	04-07-2002 20-09-1999 10-09-1999 10-09-1999 13-12-2000 19-02-2002

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82